SB 297: Valley Fever Screening and Prevention Act of 2025.
- Session Year: 2025-2026
- House: Senate
- Latest Version Date: 2025-07-07
Current Status:
In Progress
(2025-08-29: August 29 hearing: Held in committee and under submission.)
Introduced
In Committee
Awaiting First Chamber Vote
Passed First Chamber
In Committee
Awaiting Second Chamber Vote
Passed Second Chamber
Enacted
(1)Existing law establishes the State Department of Public Health to, among other things, implement and administer various programs relating to public health. Existing law, the Valley Fever Education, Early Diagnosis, and Treatment Act, states the intent of the Legislature to raise awareness of the symptoms, tests, and treatments for valley fever among the general public, primary health care providers, and health care providers who care for persons at higher risk for getting valley fever.
This bill, the Valley Fever Screening and Prevention Act of 2025, would require the department to annually analyze and identify regions with high rates of valley fever using public health surveillance data. department, in consultation with subject matter experts, to the extent feasible and using available data and resources, including public health surveillance data, to annually analyze and identify regions with elevated rates of valley fever. The bill would require the department to publish its first list of high-incidence regions for valley fever on or before March 1, 2027. The bill would require the department to provide local health departments in high-incidence regions with detailed infection data and standardized screening protocols that align with the current national clinical practice recommendations for valley fever. The bill would require the department, on or before January 1, 2030, and every 2 years thereafter, to evaluate the effectiveness of the valley fever screening and prevention program and report its findings to the Legislature.
This bill would require local health departments in high-incidence areas to conduct outreach to health care providers and the general public to raise awareness of valley fever risks, symptoms, and prevention strategies. The bill would require local health departments to annually report the number of confirmed cases of valley fever to the department, as specified. By imposing duties on local health departments, this bill would impose a state-mandated local program.
(2)Existing law provides for the licensure and regulation of health facilities and clinics by the State Department of Public Health. A violation of these provisions is a crime.
This bill, commencing January 1, 2028, would require an adult patient receiving primary care services in a facility, clinic, unlicensed clinic, center, office, or other setting, and in a high-incidence region for valley fever, to be offered a valley fever screening test, as specified. screened for valley fever, to the extent the services are covered under the patients health insurance, unless specified circumstances exist. If the results of a screening suggest that testing should be considered, the bill would require the health care provider to offer the patient diagnostic testing. If the test result is positive, the health care provider shall offer care, as specified, for valley fever management. The bill would prohibit a health care provider who fails to comply with these provisions who, based on their professional judgment, determines it is not appropriate to screen, offer to screen, or consider or offer a patient testing for valley fever from being subject to any disciplinary action related to their licensure or certification, or to any civil or criminal liability for that failure. licensure, certification, or privileges in relation to that determination. The bill would also prohibit a violation of these provisions from being the basis of civil or criminal liability.
By expanding the scope of a crime applicable to the health care settings described above, this bill would impose a state-mandated local program.
(3)Existing law establishes the Medi-Cal program, which is administered by the State Department of Health Care Services and under which qualified low-income individuals receive health care services. Existing law,(3)Existing law, the Knox-Keene Health Care Service Plan Act of 1975, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care, and makes a willful violation of the act a crime. Existing law provides for the regulation of health insurers by the Department of Insurance.
This bill would require prohibit a health care service plan contract or health insurance policy, except as specified, that is issued, amended, delivered, or renewed on or after June 1, 2027, to cover, without cost sharing, from imposing a deductible, coinsurance, copayment, or other requirement on a valley fever screening or test, as specified, in high-incidence regions for valley fever, as identified by the State Department of Public Health. fever. Because a violation of this requirement relative to health care service plans would be a crime, the bill would impose a state-mandated local program.
The bill would add the aforementioned screening tests as a Medi-Cal covered benefit, subject to any necessary federal approvals and federal financial participation, as specified.(4)The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that with regard to certain mandates no reimbursement is required by this act for a specified reason.
With regard to any other mandates, this bill would provide that, if the Commission on State Mandates determines that the bill contains costs so mandated by the state, reimbursement for those costs shall be made pursuant to the statutory provisions noted above.
(1)Existing law establishes the State Department of Public Health to, among other things, implement and administer various programs relating to public health. Existing law, the Valley Fever Education, Early Diagnosis, and Treatment Act, states the intent of the Legislature to raise awareness of the symptoms, tests, and treatments for valley fever among the general public, primary health care providers, and health care providers who care for persons at higher risk for getting valley fever.
This bill, the Valley Fever Screening and Prevention Act of 2025, would require the department to annually analyze and identify regions with high rates of valley fever using public health surveillance data. The bill would require the department to publish its first list of high-incidence regions for valley fever on or before March 1, 2027. The bill would require the department to provide local health departments in high-incidence regions with detailed infection data and standardized screening protocols for valley fever. The bill would require the department, on or before January 1, 2030, and every 2 years thereafter, to evaluate the effectiveness of the valley fever screening and prevention program and report its findings to the Legislature.
This bill would require local health departments in high-incidence regions to ensure compliance with screening protocols for valley fever. The bill would require local health departments areas to conduct outreach to health care providers and the general public to raise awareness of valley fever risks, symptoms, and prevention strategies. The bill would require local health departments to annually report the number of confirmed cases of valley fever and demographic and geographic data fever to the department, as specified. By imposing duties on local health departments, this bill would impose a state-mandated local program.
(2)Existing law provides for the licensure and regulation of health facilities and clinics by the State Department of Public Health. A violation of these provisions is a crime.
This bill, commencing January 1, 2028, would require an adult patient receiving primary care services in a facility, clinic, unlicensed clinic, center, office, or other setting, and in a high-incidence region for valley fever, to be offered a valley fever screening test, as specified. The bill would prohibit a health care provider who fails to comply with these provisions from being subject to any disciplinary action related to their licensure or certification, or to any civil or criminal liability for that failure.
By expanding the scope of a crime applicable to the health care settings described above, this bill would impose a state-mandated local program.
(3)Existing law establishes the Medi-Cal program, which is administered by the State Department of Health Care Services and under which qualified low-income individuals receive health care services. Existing law, the Knox-Keene Health Care Service Plan Act of 1975, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care, and makes a willful violation of the act a crime. Existing law provides for the regulation of health insurers by the Department of Insurance.
This bill would require a health care service plan contract or health insurance policy, except as specified, that is issued, amended, delivered, or renewed on or after June 1, 2027, to cover, without cost sharing, valley fever screening tests test, as specified, in high-incidence regions for valley fever, as identified by the State Department of Public Health. Because a violation of this requirement relative to health care service plans would be a crime, the bill would impose a state-mandated local program.
The bill would add the aforementioned screening tests as a Medi-Cal covered benefit, subject to any necessary federal approvals and federal financial participation, as specified.
(4)The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that with regard to certain mandates no reimbursement is required by this act for a specified reason.
With regard to any other mandates, this bill would provide that, if the Commission on State Mandates determines that the bill contains costs so mandated by the state, reimbursement for those costs shall be made pursuant to the statutory provisions noted above.
(1)Existing law establishes the State Department of Public Health to, among other things, implement and administer various programs relating to public health. Existing law, the Valley Fever Education, Early Diagnosis, and Treatment Act, states the intent of the Legislature to raise awareness of the symptoms, tests, and treatments for valley fever among the general public, primary health care providers, and health care providers who care for persons at higher risk for getting valley fever.
This bill, the Valley Fever Screening and Prevention Act of 2025, would require the department to annually analyze and identify regions with high rates of valley fever using public health surveillance data. The bill would require the department to publish its first list of high-incidence regions for valley fever on or before March 1, 2027. The bill would require the department to provide county local health departments in high-incidence regions with detailed infection data and standardized screening protocols for valley fever. The bill would require the department, on or before January 1, 2030, and every 2 years thereafter, to evaluate the effectiveness of the valley fever screening and prevention program and report its findings to the Legislature.
This bill would require county local health departments in high-incidence regions to coordinate with local health officers to ensure compliance with screening protocols for valley fever. The bill would require counties local health departments to conduct outreach to health care providers and the general public to raise awareness of valley fever risks, symptoms, and prevention strategies. The bill would require counties local health departments to annually report compliance the number of confirmed cases of valley fever and demographic and geographic data to the department, as specified. By imposing duties on counties, local health departments, this bill would impose a state-mandated local program.
(2)Existing law provides for the licensure and regulation of health facilities and clinics by the State Department of Public Health. A violation of these provisions is a crime.
This bill, commencing January 1, 2028, would require an adult patient receiving primary care services in a facility, clinic, unlicensed clinic, center, office, or other setting, and in a high-incidence region for valley fever, to be offered a valley fever screening test, as specified. The bill would prohibit a health care provider who fails to comply with these provisions from being subject to any disciplinary action related to their licensure or certification, or to any civil or criminal liability for that failure.
By expanding the scope of a crime applicable to the health care settings described above, this bill would impose a state-mandated local program.
(3)Existing law establishes the Medi-Cal program, which is administered by the State Department of Health Care Services and under which qualified low-income individuals receive health care services. Existing law, the Knox-Keene Health Care Service Plan Act of 1975, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care, and makes a willful violation of the act a crime. Existing law provides for the regulation of health insurers by the Department of Insurance.
This bill would require a health care service plan contract or health insurance policy, except as specified, that is issued, amended, delivered, or renewed on or after June 1, 2027, to cover, without cost sharing, valley fever screening tests in high-incidence regions for valley fever, as identified by the State Department of Public Health. Because a violation of this requirement relative to health care service plans would be a crime, the bill would impose a state-mandated local program.
The bill would add the aforementioned screening tests as a Medi-Cal covered benefit, subject to any necessary federal approvals and federal financial participation, as specified.
(4)The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that with regard to certain mandates no reimbursement is required by this act for a specified reason.
With regard to any other mandates, this bill would provide that, if the Commission on State Mandates determines that the bill contains costs so mandated by the state, reimbursement for those costs shall be made pursuant to the statutory provisions noted above.
(1)Existing law establishes the State Department of Public Health to, among other things, implement and administer various programs relating to public health. Existing law, the Valley Fever Education, Early Diagnosis, and Treatment Act, states the intent of the Legislature to raise awareness of the symptoms, tests, and treatments for valley fever among the general public, primary health care providers, and health care providers who care for persons at higher risk for getting valley fever.
This bill, the Valley Fever Screening and Prevention Act of 2025, would require the department to annually analyze and identify regions with high rates of valley fever using public health surveillance data. The bill would require the department to publish its first list of high-incidence regions for valley fever on or before March 1, 2027. The bill would require the department to provide county health departments in high-incidence regions with detailed infection data and standardized screening protocols for valley fever. The bill would require the department, on or before January 1, 2030, and every 2 years thereafter, to evaluate the effectiveness of the valley fever screening and prevention program and report its findings to the Legislature.
This bill would require county health departments in high-incidence regions to coordinate with local health officers to ensure compliance with screening protocols for valley fever. The bill would require counties to conduct outreach to health care providers and the general public to raise awareness of valley fever risks, symptoms, and prevention strategies. The bill would require counties to annually report compliance data to the department, as specified. By imposing duties on counties, this bill would impose a state-mandated local program.
(2)Existing law provides for the licensure and regulation of health facilities and clinics by the State Department of Public Health. A violation of these provisions is a crime.
This bill, commencing January 1, 2028, would require an adult patient receiving primary care services in a facility, clinic, unlicensed clinic, center, office, or other setting, and in a high-incidence region for valley fever, to be offered a valley fever screening test, as specified. The bill would prohibit a health care provider who fails to comply with these provisions from being subject to any disciplinary action related to their licensure or certification, or to any civil or criminal liability for that failure.
By expanding the scope of a crime applicable to the health care settings described above, this bill would impose a state-mandated local program.
(3)Existing law establishes the Medi-Cal program, which is administered by the State Department of Health Care Services and under which qualified low-income individuals receive health care services. Existing law, the Knox-Keene Health Care Service Plan Act of 1975, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care, and makes a willful violation of the act a crime. Existing law provides for the regulation of health insurers by the Department of Insurance.
This bill would require a health care service plan contract or health insurance policy, except as specified, that is issued, amended, delivered, or renewed on or after June 1, 2027, to cover, without cost sharing, valley fever screening tests in high-incidence regions for valley fever, as identified by the State Department of Public Health. Because a violation of this requirement relative to health care service plans would be a crime, the bill would impose a state-mandated local program.
The bill would add the aforementioned screening tests as a Medi-Cal covered benefit, subject to any necessary federal approvals and federal financial participation, as specified.
(4)The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that with regard to certain mandates no reimbursement is required by this act for a specified reason.
With regard to any other mandates, this bill would provide that, if the Commission on State Mandates determines that the bill contains costs so mandated by the state, reimbursement for those costs shall be made pursuant to the statutory provisions noted above.
This act is known, and may be cited, as the Valley Fever Screening and Prevention Act of 2025.
SEC. 2.The Legislature finds and declares all of the following:
(a)Valley fever is a significant public health concern in California, disproportionately impacting residents of arid regions.
(b)Early detection and intervention are essential to reduce the medical and economic burdens associated with severe cases of valley fever.
(c)Valley fever screening and prevention is necessary to protect the health and well-being of Californians residing in high-risk areas.
(d)Under existing Medi-Cal coverage, skin tests for valley fever are available to Medi-Cal members as part of an office visit for any Medi-Cal member experiencing symptoms. In addition, Medi-Cal covers diagnostic blood tests.
SEC. 3.Section 1316.8 is added to the Health and Safety Code, to read:1316.8.(a)Commencing January 1, 2028, an adult patient who receives primary care services in a facility, clinic, unlicensed clinic, center, office, or other setting where primary care services are provided, and in a high-incidence region for valley fever, as identified by the State Department of Public Health pursuant to Section 122480, shall be offered a valley fever screening test, screened for valley fever, to the extent these services are covered under the patients health insurance, based on the latest screening indications recommended by the latest national clinical practice guidelines, current national clinical practice recommendations, unless the health care provider reasonably believes that one of the following conditions applies:
(1)The patient is being treated for a life-threatening emergency.
(2)(A)The patient has previously been offered or has been the subject of a valley fever screening test. screened or tested for valley fever.
(B)This paragraph does not apply if the health care provider determines that the screening test should be offered again.(3)The patient lacks capacity to consent to a valley fever screening test.
(4)The patient is being treated in the emergency department of a general acute care hospital, as defined in subdivision (a) of Section 1250.
(b)(1)If a patient accepts the offer of a valley fever screening test and the test result is positive, a health care provider shall offer the patient followup health care or refer the patient to a health care provider who can provide followup health care. (2)Followup health care shall include diagnostic testing and care based on the latest national clinical practice guidelines recommended for valley fever management.(b)If the result of a valley fever screening suggests that testing should be considered, a health care provider shall offer diagnostic testing, to the extent these services are covered under the patients health insurance. If the diagnostic test result is positive, the health care provider shall offer care based on current national clinical practice recommendations for valley fever management or offer to refer the patient to a health care provider who can provide followup health care.
(c)The offering of a valley fever screening test under this section shall be culturally and linguistically appropriate.
(d)This section shall not affect the scope of practice of any health care provider or diminish any authority or legal or professional obligation of any health care provider to offer a screen or test for valley fever screening test, fever, or to provide services or care for the patient of a valley fever screening or test.
(e)A health care provider that fails to comply with the requirements of this section who, based upon their professional judgment, determines that it is not appropriate to screen, or offer to screen, a patient for valley fever, or to consider or offer a patient diagnostic testing or care for valley fever, shall not be subject to any disciplinary actions related to their licensure or certification, or to any civil or criminal liability, because of the health care providers failure to comply with the requirements of this section. licensure, certification, or privileges in relation to that determination. A violation of this section shall not be the basis of any civil or criminal liability.
(f)For purposes of this section, the following definitions apply:
(1)Followup health care includes providing medical management for valley fever according to the latest current national clinical practice guidelines. recommendations.
(2)Valley fever screening means assessing a patients clinical presentation to determine if diagnostic testing for coccidioidomycosis should be considered in accordance with current national clinical practice recommendations.
(2)(3)Valley fever screening test includes any laboratory test or tests that detect the presence of Coccidioides infection and provides confirmation of whether the patient has been infected. an active infection.
SEC. 4.Section 1367.57 is added to the Health and Safety Code, to read:1367.57.(a)A health care service plan contract, except for a specialized health care service plan contract, that is issued, amended, delivered, or renewed on or after June 1, 2027, shall cover a valley fever screening test provided pursuant to Section 1316.8 in high-incidence regions for valley fever, as identified by the State Department of Public Health pursuant to Section 122480.(b)(1)1367.57.(a)A health care service plan contract shall not impose a deductible, coinsurance, copayment, or any other cost-sharing requirement on the coverage provided pursuant to this section. a valley fever screening or test provided pursuant to Section 1316.8 in high-incidence regions for valley fever.
(2)(b)Notwithstanding paragraph (1), subdivision (a), if a health care service plan contract is a high deductible health plan as defined in Section 223(c)(2) of Title 26 of the United States Code, the contract shall not impose a deductible, coinsurance, or any other cost sharing on a valley fever screening test, or test for a covered individual that lives, works, or attends school in or that recently visited a high-incidence region for valley fever, unless not applying the deductible, coinsurance, or other cost sharing would conflict with federal requirements for high deductible health plans.
SEC. 5.The heading of Chapter 1 (commencing with Section 122475) is added to Part 7.7 of Division 105 of the Health and Safety Code, to read:1.General ProvisionsSEC. 6.Section 122475 of the Health and Safety Code is amended to read:122475.This chapter shall be known, and may be cited, as the Valley Fever Education, Early Diagnosis, and Treatment Act.
SEC. 7.Chapter 2 (commencing with Section 122480) is added to Part 7.7 of Division 105 of the Health and Safety Code, to read:2.Screening and Prevention122480.(a)(1)The State Department of Public Health shall shall, to the extent feasible and using available data and resources, annually analyze and identify regions with high elevated rates of valley fever using based on public health surveillance data. data and in consultation with subject matter experts. The department may revise its identification criteria over time in response to shifting patterns of disease incidence.
(2)The department shall publish its first list of high-incidence regions for valley fever on or before March 1, 2027.
(b)The department shall provide local health departments in high-incidence regions with detailed infection data and standardized screening protocols that align with the current national clinical practice recommendations for valley fever.
(c)The department shall develop and distribute evidence-based training materials on valley fever screening, detection, diagnosis, and treatment for health care providers.
122481.(a)Local health departments in high incidence areas shall conduct outreach to health care providers and the general public to raise awareness of valley fever risks, symptoms, and prevention strategies.
(b)Local health departments shall annually report to the State Department of Public Health the number of confirmed cases of valley fever.
122482.(a)Notwithstanding Section 10231.5 of the Government Code, on or before January 1, 2030, and every two years thereafter, the department shall evaluate the effectiveness of the valley fever screening and prevention program and report its findings to the Legislature.
(b)A report to be submitted pursuant to subdivision (a) shall be submitted in compliance with Section 9795 of the Government Code.
SEC. 8.Section 10123.25 is added to the Insurance Code, to read:10123.25.(a)A health insurance policy, except for a specialized health insurance policy, that is issued, amended, delivered, or renewed on or after June 1, 2027, shall cover a valley fever screening test provided pursuant to Section 1316.8 of the Health and Safety Code in high-incidence regions for valley fever, as identified by the State Department of Public Health pursuant to Section 122480 of the Health and Safety Code.(b)(1)10123.25.(a)A health insurance policy shall not impose a deductible, coinsurance, copayment, or any other cost-sharing requirement on the coverage provided pursuant to this section. a valley fever screening or test provided pursuant to Section 1316.8 of the Health and Safety Code in high-incidence regions for valley fever for any covered individual that lives, works, or attends school in or that recently visited any high-incidence region for valley fever.
(c)(b)Notwithstanding paragraph (1), subdivision (a), if a health insurance policy is a high deductible health plan, as defined in Section 223(c)(2) of Title 26 of the United States Code, the policy shall not impose a deductible, coinsurance, or any other cost sharing on a valley fever screening test, unless not applying the deductible, coinsurance, or other cost sharing would conflict with federal requirements for high deductible health plans.
SEC. 9.Section 14132.13 is added to the Welfare and Institutions Code, to read:14132.13.(a)Commencing on June 1, 2027, valley fever screening tests in high-incidence regions for valley fever, as identified by the State Department of Public Health pursuant to Section 122480 of the Health and Safety Code, shall be a covered benefit under the Medi-Cal program. (b)This section shall be implemented only to the extent that any necessary federal approvals are obtained and federal financial participation is available and not otherwise jeopardized. SEC. 10.SEC. 9.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution for certain costs that may be incurred by a local agency or school district because, in that regard, this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
However, if the Commission on State Mandates determines that this act contains other costs mandated by the state, reimbursement to local agencies and school districts for those costs shall be made pursuant to Part 7 (commencing with Section 17500) of Division 4 of Title 2 of the Government Code.
This act is known, and may be cited, as the Valley Fever Screening and Prevention Act of 2025.
SEC. 2.The Legislature finds and declares all of the following:
(a)Valley fever is a significant public health concern in California, disproportionately impacting residents of arid regions.
(b)Early detection and intervention are essential to reduce the medical and economic burdens associated with severe cases of valley fever.
(c)Valley fever screening and prevention is necessary to protect the health and well-being of Californians residing in high-risk areas.
SEC. 3.Section 1316.8 is added to the Health and Safety Code, to read:1316.8.(a)Commencing January 1, 2028, an adult patient who receives primary care services in a facility, clinic, unlicensed clinic, center, office, or other setting where primary care services are provided, and in a high-incidence region for valley fever, as identified by the State Department of Public Health pursuant to Section 122480, shall be offered a valley fever screening test, to the extent these services are covered under the patients health insurance, based on the latest screening indications recommended by the latest national clinical practice guidelines, unless the health care provider reasonably believes that one of the following conditions applies:
(1)The patient is being treated for a life-threatening emergency.
(2)(A)The patient has previously been offered or has been the subject of a valley fever screening test.
(B)This paragraph does not apply if the health care provider determines that the screening test should be offered again.
(3)The patient lacks capacity to consent to a valley fever screening test.
(4)The patient is being treated in the emergency department of a general acute care hospital, as defined in subdivision (a) of Section 1250.
(b)(1)If a patient accepts the offer of a valley fever screening test and the test result is positive, a health care provider shall offer the patient followup health care or refer the patient to a health care provider who can provide followup health care.
(2)Followup health care shall include diagnostic testing and care based on the latest national clinical practice guidelines recommended for valley fever management.
(c)The offering of a valley fever screening test under this section shall be culturally and linguistically appropriate.
(d)This section shall not affect the scope of practice of any health care provider or diminish any authority or legal or professional obligation of any health care provider to offer a valley fever screening test, or to provide services or care for the patient of a valley fever screening test.
(e)A health care provider that fails to comply with the requirements of this section shall not be subject to any disciplinary actions related to their licensure or certification, or to any civil or criminal liability, because of the health care providers failure to comply with the requirements of this section.
(f)For purposes of this section, the following definitions apply:
(1)Followup health care includes providing medical management for valley fever according to the latest national clinical practice guidelines.
(2)Valley fever screening test includes any laboratory test or tests that detect the presence of Coccidioides infection and provides confirmation of whether the patient has been infected.
SEC. 4.Section 1367.57 is added to the Health and Safety Code, to read:1367.57.(a)A health care service plan contract, except for a specialized health care service plan contract, that is issued, amended, delivered, or renewed on or after June 1, 2027, shall cover a valley fever screening tests test provided pursuant to Section 1316.8 in high-incidence regions for valley fever, as identified by the State Department of Public Health pursuant to Section 122480.
(b)(1)A health care service plan contract shall not impose a deductible, coinsurance, copayment, or any other cost-sharing requirement on the coverage provided pursuant to this section.
(2)Notwithstanding paragraph (1), if a health care service plan contract is a high deductible health plan as defined in Section 223(c)(2) of Title 26 of the United States Code, the contract shall not impose a deductible, coinsurance, or any other cost sharing on a valley fever screening test, unless not applying the deductible, coinsurance, or other cost sharing would conflict with federal requirements for high deductible health plans.
SEC. 5.The heading of Chapter 1 (commencing with Section 122475) is added to Part 7.7 of Division 105 of the Health and Safety Code, to read:1.General ProvisionsSEC. 6.Section 122475 of the Health and Safety Code is amended to read:122475.This chapter shall be known, and may be cited, as the Valley Fever Education, Early Diagnosis, and Treatment Act.
SEC. 7.Chapter 2 (commencing with Section 122480) is added to Part 7.7 of Division 105 of the Health and Safety Code, to read:2.Screening and Prevention122480.(a)(1)The State Department of Public Health shall annually analyze and identify regions with high rates of valley fever using public health surveillance data.
(2)The department shall publish its first list of high-incidence regions for valley fever on or before March 1, 2027.
(b)The department shall provide local health departments in high-incidence regions with detailed infection data and standardized screening protocols for valley fever.
(c)The department shall develop and distribute evidence-based training materials on valley fever detection, diagnosis, and treatment for health care providers.
122481.(a)Local health departments in high-incidence regions, as identified pursuant to Section 122480, shall ensure compliance with screening protocols for valley fever. (b)(a)Local health departments in high incidence areas shall conduct outreach to health care providers and the general public to raise awareness of valley fever risks, symptoms, and prevention strategies.
(c)(b)Local health departments shall annually report to the State Department of Public Health the number of confirmed cases of valley fever and relevant demographic and geographic data to support statewide tracking and response efforts. fever.
122482.(a)Notwithstanding Section 10231.5 of the Government Code, on or before January 1, 2030, and every two years thereafter, the department shall evaluate the effectiveness of the valley fever screening and prevention program and report its findings to the Legislature.
(b)A report to be submitted pursuant to subdivision (a) shall be submitted in compliance with Section 9795 of the Government Code.
SEC. 8.Section 10123.25 is added to the Insurance Code, to read:10123.25.(a)A health insurance policy, except for a specialized health insurance policy, that is issued, amended, delivered, or renewed on or after June 1, 2027, shall cover a valley fever screening tests test provided pursuant to Section 1316.8 of the Health and Safety Code in high-incidence regions for valley fever, as identified by the State Department of Public Health pursuant to Section 122480 of the Health and Safety Code.
(b)(1)A health insurance policy shall not impose a deductible, coinsurance, copayment, or any other cost-sharing requirement on the coverage provided pursuant to this section.
(c)Notwithstanding paragraph (1), if a health insurance policy is a high deductible health plan, as defined in Section 223(c)(2) of Title 26 of the United States Code, the policy shall not impose a deductible, coinsurance, or any other cost sharing on a valley fever screening test, unless not applying the deductible, coinsurance, or other cost sharing would conflict with federal requirements for high deductible health plans.
SEC. 9.Section 14132.13 is added to the Welfare and Institutions Code, to read:14132.13.(a)Commencing on June 1, 2027, valley fever screening tests in high-incidence regions for valley fever, as identified by the State Department of Public Health pursuant to Section 122480 of the Health and Safety Code, shall be a covered benefit under the Medi-Cal program.
(b)This section shall be implemented only to the extent that any necessary federal approvals are obtained and federal financial participation is available and not otherwise jeopardized.
SEC. 10.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution for certain costs that may be incurred by a local agency or school district because, in that regard, this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
However, if the Commission on State Mandates determines that this act contains other costs mandated by the state, reimbursement to local agencies and school districts for those costs shall be made pursuant to Part 7 (commencing with Section 17500) of Division 4 of Title 2 of the Government Code.
This act is known, and may be cited, as the Valley Fever Screening and Prevention Act of 2025.
SEC. 2.The Legislature finds and declares all of the following:
(a)Valley fever is a significant public health concern in California, disproportionately impacting residents of arid regions.
(b)Early detection and intervention are essential to reduce the medical and economic burdens associated with severe cases of valley fever.
(c)Valley fever screening and prevention is necessary to protect the health and well-being of Californians residing in high-risk areas.
SEC. 3.Section 1316.8 is added to the Health and Safety Code, to read:1316.8.(a)Commencing January 1, 2028, an adult patient who receives primary care services in a facility, clinic, unlicensed clinic, center, office, or other setting where primary care services are provided, and in a high-incidence region for valley fever, as identified by the State Department of Public Health pursuant to Section 122480, shall be offered a valley fever screening test, to the extent these services are covered under the patients health insurance, based on the latest screening indications recommended by the latest national clinical practice guidelines, unless the health care provider reasonably believes that one of the following conditions applies:
(1)The patient is being treated for a life-threatening emergency.
(2)(A)The patient has previously been offered or has been the subject of a valley fever screening test.
(B)This paragraph does not apply if the health care provider determines that the screening test should be offered again.
(3)The patient lacks capacity to consent to a valley fever screening test.
(4)The patient is being treated in the emergency department of a general acute care hospital, as defined in subdivision (a) of Section 1250.
(b)(1)If a patient accepts the offer of a valley fever screening test and the test result is positive, a health care provider shall offer the patient followup health care or refer the patient to a health care provider who can provide followup health care.
(2)Followup health care shall include diagnostic testing and care based on the latest national clinical practice guidelines recommended for valley fever management.
(c)The offering of a valley fever screening test under this section shall be culturally and linguistically appropriate.
(d)This section shall not affect the scope of practice of any health care provider or diminish any authority or legal or professional obligation of any health care provider to offer a valley fever screening test, or to provide services or care for the patient of a valley fever screening test.
(e)A health care provider that fails to comply with the requirements of this section shall not be subject to any disciplinary actions related to their licensure or certification, or to any civil or criminal liability, because of the health care providers failure to comply with the requirements of this section.
(f)For purposes of this section, the following definitions apply:
(1)Followup health care includes providing medical management for valley fever according to the latest national clinical practice guidelines.
(2)Valley fever screening test includes any laboratory test or tests that detect the presence of Coccidioides infection and provides confirmation of whether the patient has been infected.
SEC. 4.Section 1367.57 is added to the Health and Safety Code, to read:1367.57.(a)A health care service plan contract, except for a specialized health care service plan contract, that is issued, amended, delivered, or renewed on or after June 1, 2027, shall cover valley fever screening tests in high-incidence regions for valley fever, as identified by the State Department of Public Health pursuant to Section 122480.
(b)A health care service plan contract shall not impose a deductible, coinsurance, copayment, or any other cost-sharing requirement on the coverage provided pursuant to this section.
SEC. 5.The heading of Chapter 1 (commencing with Section 122475) is added to Part 7.7 of Division 105 of the Health and Safety Code, to read:1.General ProvisionsSEC. 6.Section 122475 of the Health and Safety Code is amended to read:122475.This chapter shall be known, and may be cited, as the Valley Fever Education, Early Diagnosis, and Treatment Act.
SEC. 7.Chapter 2 (commencing with Section 122480) is added to Part 7.7 of Division 105 of the Health and Safety Code, to read:2.Screening and Prevention122480.(a)(1)The State Department of Public Health shall annually analyze and identify regions with high rates of valley fever using public health surveillance data.
(2)The department shall publish its first list of high-incidence regions for valley fever on or before March 1, 2027.
(b)The department shall provide county local health departments in high-incidence regions with detailed infection data and standardized screening protocols for valley fever.
(c)The department shall develop and distribute evidence-based training materials on valley fever detection, diagnosis, and treatment for health care providers.
122481.(a)County Local health departments in high-incidence regions, as identified pursuant to Section 122480, shall coordinate with local health officers to ensure compliance with screening protocols for valley fever.
(b)Counties Local health departments shall conduct outreach to health care providers and the general public to raise awareness of valley fever risks, symptoms, and prevention strategies.
(c)County Local health departments shall annually report compliance data to the State Department of Public Health, including Health the number of screenings conducted and confirmed cases of valley fever. fever and relevant demographic and geographic data to support statewide tracking and response efforts.
122482.(a)Notwithstanding Section 10231.5 of the Government Code, on or before January 1, 2030, and every two years thereafter, the department shall evaluate the effectiveness of the valley fever screening and prevention program and report its findings to the Legislature.
(b)A report to be submitted pursuant to subdivision (a) shall be submitted in compliance with Section 9795 of the Government Code.
SEC. 8.Section 10123.25 is added to the Insurance Code, to read:10123.25.(a)A health insurance policy, except for a specialized health insurance policy, that is issued, amended, delivered, or renewed on or after June 1, 2027, shall cover valley fever screening tests in high-incidence regions for valley fever, as identified by the State Department of Public Health pursuant to Section 122480 of the Health and Safety Code.
(b)A health insurance policy shall not impose a deductible, coinsurance, copayment, or any other cost-sharing requirement on the coverage provided pursuant to this section.
SEC. 9.Section 14132.13 is added to the Welfare and Institutions Code, to read:14132.13.(a)Commencing on June 1, 2027, valley fever screening tests in high-incidence regions for valley fever, as identified by the State Department of Public Health pursuant to Section 122480 of the Health and Safety Code, shall be a covered benefit under the Medi-Cal program.
(b)This section shall be implemented only to the extent that any necessary federal approvals are obtained and federal financial participation is available and not otherwise jeopardized.
SEC. 10.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution for certain costs that may be incurred by a local agency or school district because, in that regard, this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
However, if the Commission on State Mandates determines that this act contains other costs mandated by the state, reimbursement to local agencies and school districts for those costs shall be made pursuant to Part 7 (commencing with Section 17500) of Division 4 of Title 2 of the Government Code.
This act is known, and may be cited, as the Valley Fever Screening and Prevention Act of 2025.
SEC. 2.The Legislature finds and declares all of the following:
(a)Valley fever is a significant public health concern in California, disproportionately impacting residents of arid regions.
(b)Early detection and intervention are essential to reduce the medical and economic burdens associated with severe cases of valley fever.
(c)Valley fever screening and prevention is necessary to protect the health and well-being of Californians residing in high-risk areas.
SEC. 3.Section 1316.8 is added to the Health and Safety Code, to read:1316.8.(a)Commencing January 1, 2028, an adult patient who receives primary care services in a facility, clinic, unlicensed clinic, center, office, or other setting where primary care services are provided, and in a high-incidence region for valley fever, as identified by the State Department of Public Health pursuant to Section 122480, shall be offered a valley fever screening test, to the extent these services are covered under the patients health insurance, based on the latest screening indications recommended by the latest national clinical practice guidelines, unless the health care provider reasonably believes that one of the following conditions applies:
(1)The patient is being treated for a life-threatening emergency.
(2)(A)The patient has previously been offered or has been the subject of a valley fever screening test.
(B)This paragraph does not apply if the health care provider determines that the screening test should be offered again.
(3)The patient lacks capacity to consent to a valley fever screening test.
(4)The patient is being treated in the emergency department of a general acute care hospital, as defined in subdivision (a) of Section 1250.
(b)(1)If a patient accepts the offer of a valley fever screening test and the test result is positive, a health care provider shall offer the patient followup health care or refer the patient to a health care provider who can provide followup health care.
(2)Followup health care shall include diagnostic testing and care based on the latest national clinical practice guidelines recommended for valley fever management.
(c)The offering of a valley fever screening test under this section shall be culturally and linguistically appropriate.
(d)This section shall not affect the scope of practice of any health care provider or diminish any authority or legal or professional obligation of any health care provider to offer a valley fever screening test, or to provide services or care for the patient of a valley fever screening test.
(e)A health care provider that fails to comply with the requirements of this section shall not be subject to any disciplinary actions related to their licensure or certification, or to any civil or criminal liability, because of the health care providers failure to comply with the requirements of this section.
(f)For purposes of this section, the following definitions apply:
(1)Followup health care includes providing medical management for valley fever according to the latest national clinical practice guidelines.
(2)Valley fever screening test includes any laboratory test or tests that detect the presence of Coccidioides infection and provides confirmation of whether the patient has been infected.
SEC. 4.Section 1367.57 is added to the Health and Safety Code, to read:1367.57.(a)A health care service plan contract, except for a specialized health care service plan contract, that is issued, amended, delivered, or renewed on or after June 1, 2027, shall cover valley fever screening tests in high-incidence regions for valley fever, as identified by the State Department of Public Health pursuant to Section 122480.
(b)A health care service plan contract shall not impose a deductible, coinsurance, copayment, or any other cost-sharing requirement on the coverage provided pursuant to this section.
SEC. 5.The heading of Chapter 1 (commencing with Section 122475) is added to Part 7.7 of Division 105 of the Health and Safety Code, to read:1.General ProvisionsSEC. 6.Section 122475 of the Health and Safety Code is amended to read:122475.This part chapter shall be known, and may be cited, as the Valley Fever Education, Early Diagnosis, and Treatment Act.
SEC. 7.Chapter 2 (commencing with Section 122480) is added to Part 7.7 of Division 105 of the Health and Safety Code, to read:2.Screening and Prevention122480.(a)(1)The State Department of Public Health shall annually analyze and identify regions with high rates of valley fever using public health surveillance data.
(2)The department shall publish its first list of high-incidence regions for valley fever on or before March 1, 2027.
(b)The department shall provide county health departments in high-incidence regions with detailed infection data and standardized screening protocols for valley fever.
(c)The department shall develop and distribute evidence-based training materials on valley fever detection, diagnosis, and treatment for health care providers.
122481.(a)County health departments in high-incidence regions, as identified pursuant to Section 122480, shall coordinate with local health officers to ensure compliance with screening protocols for valley fever.
(b)Counties shall conduct outreach to health care providers and the general public to raise awareness of valley fever risks, symptoms, and prevention strategies.
(c)County health departments shall annually report compliance data to the State Department of Public Health, including the number of screenings conducted and confirmed cases of valley fever.
122482.(a)Notwithstanding Section 10231.5 of the Government Code, on or before January 1, 2030, and every two years thereafter, the department shall evaluate the effectiveness of the valley fever screening and prevention program and report its findings to the Legislature.
(b)A report to be submitted pursuant to subdivision (a) shall be submitted in compliance with Section 9795 of the Government Code.
SEC. 8.Section 10123.25 is added to the Insurance Code, to read:10123.25.(a)A health insurance policy, except for a specialized health insurance policy, that is issued, amended, delivered, or renewed on or after June 1, 2027, shall cover valley fever screening tests in high-incidence regions for valley fever, as identified by the State Department of Public Health pursuant to Section 122480 of the Health and Safety Code.
(b)A health insurance policy shall not impose a deductible, coinsurance, copayment, or any other cost-sharing requirement on the coverage provided pursuant to this section.
SEC. 9.Section 14132.13 is added to the Welfare and Institutions Code, to read:14132.13.(a)Commencing on June 1, 2027, valley fever screening tests in high-incidence regions for valley fever, as identified by the State Department of Public Health pursuant to Section 122480 of the Health and Safety Code, shall be a covered benefit under the Medi-Cal program.
(b)This section shall be implemented only to the extent that any necessary federal approvals are obtained and federal financial participation is available and not otherwise jeopardized.
SEC. 10.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution for certain costs that may be incurred by a local agency or school district because, in that regard, this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
However, if the Commission on State Mandates determines that this act contains other costs mandated by the state, reimbursement to local agencies and school districts for those costs shall be made pursuant to Part 7 (commencing with Section 17500) of Division 4 of Title 2 of the Government Code.
|
Date
|
Status
|
|---|---|
| Aug 29, 2025 | August 29 hearing: Held in committee and under submission. |
| Aug 20, 2025 | August 20 set for first hearing. Placed on APPR. suspense file. |
| Jul 16, 2025 | From committee: Do pass and re-refer to Com. on APPR. (Ayes 12. Noes 0.) (July 15). Re-referred to Com. on APPR. |
| Jul 7, 2025 | From committee with author's amendments. Read second time and amended. Re-referred to Com. on JUD. |
| Jul 7, 2025 | July 8 hearing postponed by committee. |
| Jul 2, 2025 | From committee: Do pass and re-refer to Com. on JUD. (Ayes 14. Noes 0.) (July 1). Re-referred to Com. on JUD. |
| Jun 5, 2025 | Referred to Coms. on HEALTH and JUD. |
| May 28, 2025 | In Assembly. Read first time. Held at Desk. |
| May 28, 2025 | Read third time. Passed. (Ayes 37. Noes 0. Page 1300.) Ordered to the Assembly. |
| May 23, 2025 | Read second time. Ordered to third reading. |
| May 23, 2025 | From committee: Do pass. (Ayes 6. Noes 0. Page 1195.) (May 23). |
| May 16, 2025 | Set for hearing May 23. |
| May 12, 2025 | May 12 hearing: Placed on APPR. suspense file. |
| May 2, 2025 | Set for hearing May 12. |
| Apr 30, 2025 | From committee: Do pass and re-refer to Com. on APPR. (Ayes 12. Noes 0. Page 939.) (April 29). Re-referred to Com. on APPR. |
| Apr 17, 2025 | Set for hearing April 29. |
| Apr 10, 2025 | Read second time and amended. Re-referred to Com. on JUD. |
| Apr 10, 2025 | From committee: Do pass as amended and re-refer to Com. on JUD. (Ayes 10. Noes 0. Page 736.) (April 9). |
| Apr 2, 2025 | From committee with author's amendments. Read second time and amended. Re-referred to Com. on HEALTH. |
| Mar 28, 2025 | Set for hearing April 9. |
| Mar 26, 2025 | April 2 set for first hearing canceled at the request of author. |
| Mar 17, 2025 | Set for hearing April 2. |
| Feb 19, 2025 | Referred to Coms. on HEALTH and JUD. |
| Feb 11, 2025 | From printer. May be acted upon on or after March 13. |
| Feb 10, 2025 | Introduced. Read first time. To Com. on RLS. for assignment. To print. |
|
Date
|
Description
|
Location
|
Votes
|
|
|---|---|---|---|---|
| Jul 15, 2025 | Do pass and be re-referred to the Committee on [Appropriations] | Assembly Standing Committee on Judiciary |
Passed |
|
| Jul 1, 2025 | Do pass and be re-referred to the Committee on [Judiciary] | Assembly Standing Committee on Health |
Passed |
|
| May 28, 2025 | Senate 3rd Reading SB297 Hurtado | Senate Floor |
Passed |
|
| May 23, 2025 | Do pass | Senate Standing Committee on Appropriations |
Passed |
|
| May 12, 2025 | Placed on suspense file | Senate Standing Committee on Appropriations |
Passed |
|
| Apr 29, 2025 | Do pass, but first be re-referred to the Committee on [Appropriations] | Senate Standing Committee on Judiciary |
Passed |
|
| Apr 9, 2025 | Do pass as amended, but first amend, and re-refer to the Committee on [Judiciary] | Senate Standing Committee on Health |
Passed |
This list shows positions taken on this bill by organizations on the date displayed, which is linked to the original source.
Positions by individuals are not included.
|
Organization
|
Position
|
Date
|
|---|---|---|
| Altura Centers For Health | ** Support | |
| Aria Community Health Center | ** Support | |
| Association Of California Life & Health Insurance Companies | ** Against | |
| California Association Of Health Plans | ** Against | |
| California Health Collaborative | ** Support | |
| California Medical Association | ** Against | |
| Center on Race, Poverty & the Environment | ** Support | |
| city of avenal | ** Support | |
| County Health Executives Association Of California | ** Against | |
| Kern Medical | ** Support | |
| MyCare Foundation | ** Support | |
| Saint Agnes Medical Center | ** Support | |
| Sierra View Medical Center | ** Support | |
| Southern California Contractors Association | ** Support | |
| Valley Fever Americas Foundation | ** Support | |
| Valley Fever Institute at Kern Medicine | ** Support |
Date of Hearing: August 20, 2025
ASSEMBLY COMMITTEE ON APPROPRIATIONS
Buffy Wicks, Chair
SBPCA Bill Id:SB 297
Author:(Hurtado) – As Amended Ver:July 7, 2025
Policy Committee: | Health | Vote: | 14 - 0 |
Judiciary | 12 - 0 | ||
|
|
Urgency: No State Mandated Local Program: Yes Reimbursable: Yes
SUMMARY:
This bill requires (1) the California Department of Public Health (CDPH) provide local health departments (LHDs) with valley fever infection data and screening protocols, and (2) LHDs in high-incidence areas raise awareness of valley fever among health care providers and the general public. The bill also requires a patient receiving primary care in a high-incidence region be screened for valley fever and offered testing and care, as appropriate, without cost sharing.
Specifically, major provisions of this bill:
- Require, commencing January 1, 2028, an adult patient who receives primary care services in a facility, clinic, unlicensed clinic, center, office, or other setting where primary care services are provided, and in a high-incidence region for valley fever, as identified by CDPH pursuant to item 6, below, be screened for valley fever to the extent these services are covered under the patient’s health insurance, based on the current national clinical practice recommendations, except as specified.
- If the result of a valley fever screening suggests testing should be considered, require a health care provider offer diagnostic testing, to the extent these services are covered under the patient’s health insurance. If the diagnostic test result is positive, requires the health care provider offer care based on current national clinical practice recommendations and in a culturally and linguistically appropriate manner, or offer to refer the patient to a health care provider who can provide followup health care.
- Prohibit a health care provider who, based upon their professional judgement, determines it is not appropriate to screen or offer to screen a patient for valley fever or to consider or offer a patient diagnostic testing or care for Valley Fever from being subject to any disciplinary action related to their licensure, certification, or privileges in relation to that determination. Further prohibits a violation of the bill’s requirements from being the basis of any civil or criminal liability.
- Defines the following for purposes of the bill:
- “Followup health care” includes providing medical management for valley fever according to the current national practice recommendations.
- “Valley fever screening” means assessing a patient’s clinical presentation to determine if diagnostic testing should be considered in accordance with current national clinical practice recommendations.
- Prohibits a health plan contract or health insurance policy from imposing a deductible, coinsurance, copayment, or any other cost-sharing requirement for a valley fever screening or test provided pursuant to the bill for any covered individual that lives, works, attends school or has recently visited any high incidence region, except as specified.
- Requires CDPH, to the extent feasible and using available data and resources, annually analyze and identify regions with elevated rates of valley fever based on public health surveillance data and in consultation with subject matter experts, and publish the first list of high incidence regions on or before March 1, 2027.
- Requires CDPH provide local health departments in high-incidence regions with detailed infection data and standardized screening protocols that align with current national clinical practice recommendations for valley fever.
- Requires CDPH develop and distribute evidence-based training materials on valley fever screening, detection, diagnosis, and treatment for health care providers.
- Requires LHDs in high incidence areas conduct outreach to health care providers and the general public to raise awareness of valley fever risks, symptoms, and prevention strategies.
- Requires LHDs annually report to CDPH the number of confirmed cases of valley fever.
- Requires CDPH, on or before January 1, 2030 and every two years thereafter, evaluate the effectiveness of the valley fever screening and prevention program and report its findings to the Legislature.
FISCAL EFFECT:
CDPH estimates ongoing costs of $586,000 per year, starting in Fiscal Year (FY) 2026-27 to cover three positions to support surveillance, data analysis, dissemination, development of screening protocols, public and provider education, investigations, and evaluation efforts, as well as software, needed to implement the provisions of the bill (General Fund).
According to the County Health Executives Association of California (CHEAC), LHDs in the central valley counties report that outreach activities are not included in their budgets due to funding reductions. CHEAC states counties reported annual costs for activities required by this bill in the range of approximately $20,000 to $265,000 per county, depending on the size of the jurisdiction and the scope of activities, which could include public service announcements (radio and TV), outreach and education for health care providers, development and distribution of educational materials, staff time (epidemiologists, health educators, equity staff), and health care provider educational symposia. If ten counties are required to conduct outreach and other activities, cumulative annual costs could reach hundreds of thousands of dollars or more. If the Commission on State Mandates determines these costs are reimbursable, the state would be required to pay these costs (General Fund).
The Department of Insurance estimates a one-time cost of $6,000 in FY 2025-26 (Insurance Fund).
The Department of Managed Health Care estimates minor and absorbable costs.
No costs to the Department of Health Care Services for the Medi-Cal program.
The California Public Employees Retirement System (CalPERS) anticipates minimal costs.
Additional costs to health plans and insurers of an unknown amount, to the extent this bill increases testing and treatment for valley fever, and these services are not already covered without cost sharing, such as copays or deductibles.
COMMENTS:
- Purpose. According to the author:
Valley Fever is a growing public health crisis, yet too many cases go undiagnosed for too long. [This bill] ensures that Californians in high-incidence regions receive the early detection and care they deserve. …By equipping communities with better data, removing cost barriers, and prioritizing early detection, this bill takes a critical step toward reducing the devastating impact of Valley Fever.
- Background. Valley fever, also known as coccidioidomycosis or “cocci,” is caused by the Coccidioides fungus that grows in the soil and dirt in some areas of the southwestern United States. This fungus can infect the lungs and cause respiratory symptoms, including cough, difficulty breathing, fever, and tiredness or fatigue. In rare cases, the fungus can spread to other parts of the body and cause severe disease and death. When soil or dirt is stirred up by strong winds or digging, dust containing the spores can get into the air. Anyone who lives, works, or travels in an area where the fungus grows can breathe in Coccidioides spores from outdoor dust and become infected, but those in construction, agriculture, landscaping, and mining are at higher risk. Valley fever does not spread from one person to another.
In California, the number of reported valley fever cases has increased in recent years. The number of cases increased from fewer than 1,000 cases in 2000 to more than 9,000 cases in 2019. Most cases of valley fever in California are reported from the Central Valley and Central Coast regions of the state, but the number of cases has also been increasing in the northern Central Valley and southern coastal areas of California.
Reporting of Valley Fever. Valley fever is already a reportable condition under state law. A health care provider must report suspected and confirmed cases to the LHD, which must then report to CDPH. CDPH tracks and publishes data on valley fever in monthly updates and year-end updates. CDPH also periodically publishes valley fever reports in journals, including surveillance summaries, analyses of hospital and death data, and reports summarizing valley fever outbreaks.
Valley Fever Awareness Campaign. AB 1790 (Salas and Grayson), Chapter 338, Statutes of 2018, provided resources for CDPH to create a campaign to spread awareness about valley fever to LHDs, healthcare providers, and the public. CDPH conducted the campaign in 2019 and 2020.
Analysis Prepared by: Allegra Kim / APPR. / (916) 319-2081
Date of Hearing: July 15, 2025
ASSEMBLY COMMITTEE ON JUDICIARY
Ash Kalra, Chair
SBPCA Bill Id:SB 297
Author:(Hurtado) – As Amended Ver:July 7, 2025
SENATE VOTE: 37-0
SUBJECT: VALLEY FEVER SCREENING AND PREVENTION ACT OF 2025
KEY ISSUE: SHOULD ALL ADULT PATIENTS RECEIVING PRIMARY CARE SERVICES IN A HIGH-INCIDENCE REGION FOR VALLEY FEVER BE OFFERED VALLEY FEVER SCREENING; AND SHOULD HEALTH CARE PROVIDERS WHO DETERMINE, BASED UPON THEIR PROFESSIONAL JUDGEMENT, THAT SCREENING IS NOT APPROPRIATE, BE PROTECTED FROM DISCIPLINARY ACTION AND CIVIL OR CRIMINAL LIABILITY FOR EXERCISING THEIR JUDGMENT?
SYNOPSIS
Valley fever is an invasive fungal disease that cannot be reliably distinguished from other causes of respiratory illness by signs or symptoms alone. It is commonly misdiagnosed and inappropriately treated. Valley fever affects approximately 10,000 to 20,000 people each year. This author-sponsored bill requires an adult patient receiving primary care services in specified health care settings in high-incidence regions for valley fever to be offered valley fever screening. It also provides that health care providers who determine, based upon their professional judgement, that screening is not appropriate, are protected from disciplinary action and civil or criminal liability for exercising their judgment.
Most of the bill’s provisions are in the jurisdiction of the Assembly Committee on Health, which recently approved the bill by a vote of 14-0. The author agreed to amendments in that committee to clarify that “screening,” not “testing” for Valley Fever is required. Relevant to this Committee, the bill provides that a health care provider who determines, based upon their professional judgement, that screening is not appropriate, is protected from disciplinary action and civil or criminal liability for exercising their judgment, which is the focus of this analysis. Recent amendments (July 7, 2025) made minor changes to the bill’s immunity language in a manner that respects and defers to the professional judgment and discretion of medical professionals and maintain the author’s preference for mandatory screenings of certain populations, but limits to some extent the unintended negative consequences of providing complete immunity to medical providers.
The bill is supported by a number of Central Valley health care groups and advocacy organizations; the City of Avenal; the Center on Race, Poverty & the Environment; and one individual, among others. It is opposed by the Association of California Life & Health Insurance Companies and the California Association of Health Plans. The County Health Executives Association of California are opposed to the bill, unless amended, to provide funding for its mandate.
SUMMARY: Requires an adult patient receiving primary care services in specified health care settings in a high-incidence region for valley fever to be offered valley fever screening and provides that health care providers who determine, based upon their professional judgement, that screening is not appropriate, are protected from disciplinary action and civil or criminal liability for exercising their judgment. Specifically, this bill:
- On behalf of the Legislature, finds and declares all of the following:
- Valley fever is a significant public health concern in California, disproportionately impacting residents of arid regions.
- Early detection and intervention are essential to reduce the medical and economic burdens associated with severe cases of valley fever.
- Valley fever screening and prevention is necessary to protect the health and well-being of Californians residing in high-risk areas.
- Under existing Medi-Cal coverage, skin test screenings for Valley fever are available to Medi-Cal members as part of an office visit for any Medi-Cal member experiencing symptoms. In addition, Medi-Cal covers diagnostic blood tests.
- Provides that, commencing January 1, 2028, an adult patient who receives primary care services in a facility, clinic, unlicensed clinic, center, office, or other setting where primary care services are provided, and in a high-incidence region for valley fever, as identified by the State Department of Public Health, shall be screened for valley fever to the extent these services are covered under the patient’s health insurance, based on the current national clinical practice recommendations, unless the health care provider reasonably believes that one of the following conditions applies:
- The patient is being treated for a life-threatening emergency.
- The patient has previously been screened or tested for valley fever.
- The patient lacks capacity to consent to a valley fever screening test.
- The patient is being treated in the emergency department of a general acute care hospital.
- Provides that if the result of a valley fever screening suggests that testing should be considered, a health care provider shall offer diagnostic testing, to the extent these services are covered under the patient’s health insurance. If the diagnostic test result is positive, the health care provider shall offer care based on current national clinical practice recommendations for valley fever management or offer to refer the patient to a health care provider who can provide followup health care.
- Requires the offering of a valley fever screening test under this section to be culturally and linguistically appropriate.
- Clarifies that the above provisions do not affect the scope of practice of any health care provider or diminish any authority or legal or professional obligation of any health care provider to offer a screen or test for valley fever, or to provide services or care for the patient of a valley fever screening or test.
- Provides that a health care provider who, based upon their professional judgement, determines that it is not appropriate to screen or offer to screen a patient for Valley Fever or to consider or offer a patient diagnostic testing or care for Valley Fever, shall not be subject to any disciplinary action related to their licensure, certification, or privileges in relation to that determination. Further provides that a violation of the bill’s requirements shall not be the basis of any civil or criminal liability.
- Defines the following for purposes of the above:
- “Followup health care” includes providing medical management for valley fever according to the current national practice recommendations.
- “Valley fever screening” means assessing a patient’s clinical presentation to determine if diagnostic testing for coccidioidomycosis should be considered in accordance with current national clinical practice recommendations.
- Provides that a health care service plan contract shall not impose a deductible, coinsurance, copayment, or any other cost-sharing requirement for a valley fever screening or test provided pursuant to the bill in high-incidence regions for valley fever.
- Provides that, notwithstanding 8), if a health care service plan contract is a high deductible health plan, the contract shall not impose a deductible, coinsurance, or any other cost sharing on a valley fever screening or test for any covered individual that lives, works, attends school or that recently visited any high incidence region for valley fever, unless not applying the deductible, coinsurance, or other cost sharing would conflict with federal requirements for high deductible health plans.
- Requires the State Department of Public Health, to the extent feasible and using available data and resources, to annually analyze and identify regions with elevated rates of valley fever based on public health surveillance data and in consultation with subject matter experts.
- Clarifies that the department may revise its identification criteria over time in response to shifting patterns of disease incidence.
- Requires the department to publish its first list of high-incidence regions for valley fever on or before March 1, 2027.
- Requires the department to provide local health departments in high-incidence regions with detailed infection data and standardized screening protocols that align with the current national clinical practice recommendations for valley fever.
- The department shall develop and distribute evidence-based training materials on valley fever screening, detection, diagnosis, and treatment for health care providers.
- Requires local health departments in high incidence areas to conduct outreach to health care providers and the general public to raise awareness of valley fever risks, symptoms, and prevention strategies; and requires departments to annually report to the State Department of Public Health the number of confirmed cases of valley fever.
- Provides that on or before January 1, 2030, and every two years thereafter, the department shall evaluate the effectiveness of the valley fever screening and prevention program and report its findings to the Legislature; and specifies that the report is to be submitted in compliance with Section 9795 of the Government Code.
- Provides that a health insurance policy shall not impose a deductible, coinsurance, copayment, or any other cost-sharing requirement on a valley fever screening or test provided pursuant to the bill in high-incidence regions for valley fever for any covered individual that lives, works, attends school or has recently visited any high incidence region for valley fever.
- Provides that notwithstanding 13), if a health insurance policy is a high deductible health plan, the policy shall not impose a deductible, coinsurance, or any other cost sharing on a valley fever screening test, unless not applying the deductible, coinsurance, or other cost sharing would conflict with federal requirements for high deductible health plans.
EXISTING LAW:
- Requires that an adult patient who receives primary care services in a facility, clinic, unlicensed clinic, center, office, or other setting where primary care services are provided, shall be offered a hepatitis B screening test and a hepatitis C screening test, to the extent these services are covered under the patient’s health insurance. (Health & Safety Code Section 1316.7 (a).)
- Provides that a health care provider that fails to comply with the requirements of this section shall not be subject to any disciplinary actions related to their licensure or certification, or to any civil or criminal liability, because of the health care provider’s failure to comply with the requirements of this section. (Id., at (e).)
- Requires that a patient who is 18 years of age or older and who receives health care services in a facility, clinic, center, office, or other setting, where primary care services are provided, shall be offered a tuberculosis screening, including, but not limited to, assessment for tuberculosis risk and appropriate followup, if tuberculosis risk factors are identified, to the extent these services are covered under the patient’s health care coverage, based on the latest screening indications recommended by the State Department of Public Health, the federal Centers for Disease Control and Prevention, the American Thoracic Society, or the United States Preventive Services Task Force. (Health & Safety Code Section 121560 (a).)
- Provides that a health care provider that fails to comply with the requirements of this section shall not be subject to any disciplinary actions related to their licensure or certification, or to any civil or criminal liability, because of the health care provider’s failure to comply with the requirements of this section. (Id., at (f).)
- Provides that a provider of health care, as defined in Section 56.05 of the Civil Code, its officers, employees, agents, and subcontractors, who are defended by the Attorney General pursuant to Section 12511.5, or other legal counsel provided by the state, shall be indemnified in accordance with Section 825, subject to the same conditions and limitations applicable to state employees, except that no provider of health care shall be indemnified in a civil rights action unless the health care provider maintains insurance for professional negligence. To the extent that negligence constitutes the basis of liability of the health care provider, the provider’s private insurance shall be the source of recovery. (Gov. Code 827.)
FISCAL EFFECT: As currently in print this bill is keyed fiscal.
COMMENTS: This author-sponsored bill requires an adult patient receiving primary care services in specified health care settings in high-incidence regions for valley fever to be offered valley fever screening. It also provides that health care providers who determine, based upon their professional judgement, that screening is not appropriate, are protected from disciplinary action and civil or criminal liability for exercising their judgment. According to the author:
Valley Fever is a growing public health crisis, yet too many cases go undiagnosed for too long. SB 297 ensures that Californians in high-incidence regions receive the early detection and care they deserve. . . .
No one should have to choose between affordability and their health—so beginning in 2027, insurance plans, including Medi-Cal (pending federal approval), will cover these tests without cost-sharing.
Public health should be proactive, not reactive. SB 297 strengthens California’s response by requiring ongoing program assessments and legislative reports to ensure effectiveness. By equipping communities with better data, removing cost barriers, and prioritizing early detection, this bill takes a critical step toward reducing the devastating impact of Valley Fever. Californians deserve a healthcare system that catches Valley Fever early—before it catches them.
Valley fever is an invasive fungal disease that cannot be reliably distinguished from other causes of respiratory illness by signs or symptoms alone. It is commonly misdiagnosed and inappropriately treated. Valley fever affects approximately 10,000 to 20,000 people each year. Most of these reported cases occur in California and Arizona.
To respond to this increased incidence of valley fever in certain California communities, this bill requires patients to be offered valley fever screening based on screening indications recommended by the latest national clinical practice guidelines, to the extent these services are covered under the patient’s health insurance, and certain conditions are met. There are reporting requirements for state and local health entities and provisions related to health care coverage.
Most of the bill’s provisions are in the jurisdiction of the Assembly Committee on Health, which recently approved the bill by a vote of 14-0. The author agreed in the Health Committee to clarify that “screening” but not “testing” for Valley Fever is required by the bill. Relevant to this Committee, the bill provides that a health care provider who determines, based upon their professional judgement, that screening is not appropriate, is protected from disciplinary action and civil or criminal liability for exercising their judgment, which is the focus of this analysis.
The bill, prior to being amended on July 7, 2025, provided that a health care provider, “shall not be subject to any disciplinary actions related to their licensure or certification, or to any civil or criminal liability, because of the health care provider’s failure to comply with the requirements of this section.”
This language is closely modeled on immunity language codified by AB 789 (Low, Ch. 470, Stats. 2021) [requiring screening for hepatitis B and C]; and AB 2132 (Low, Ch. 951, Stats. 2024) [requiring screening for tuberculosis], neither of which were referred to this Committee. The language of the bill prior to the July 7th amendments—and the immunity language enacted by AB 789 and AB 2132--arguably was much more expansive than it should or had to be. The language implied that, despite the bill’s mandate for screening, that there can be no legal consequences whatsoever for a health care provider’s failure to comply with the screening requirement, regardless of the circumstances. By stating that the provider “shall not be subject to any disciplinary actions related to their licensure or certification” or subject to “any civil or criminal liability” for failure to comply with the requirements of the bill, the prior immunity language could have been interpreted to mean that a violation of the requirements could not ever be considered, even in a disciplinary, civil, or criminal proceeding not directly related to the violation, but in which the violation was relevant. So hypothetically, if a physician had a pattern and history or denying preventative care or treatment to patients--perhaps on the basis of their race, sex, or gender identity--evidence of them denying a Valley Fever Screening test could not be considered as evidence as part of a pattern of that discriminatory conduct. This is counterproductive to both the axiom that everyone –including health care providers –should be responsible for their misconduct, but also to the bill’s goal of promoting screening or testing for Valley Fever in appropriate circumstances.
Recent amendments (July 7, 2025) made the following minor changes to the bill’s immunity language. The modified language respects and defers to the professional judgment and discretion of medical professionals and also maintain the author’s preference for mandatory screenings of certain populations, but also limits to some extent the unintended negative consequences of providing complete immunity to medical providers:
(e) A health care provider that fails to comply with the requirements of this section who, based upon their professional judgement, determines that it is not appropriate to screen or offer to screen a patient for Valley Fever or to consider or offer a patient diagnostic testing or care for Valley Fever, shall not be subject to any disciplinary action related to their licensure, or certification, or to privileges in relation to that determination. A violation of this section shall not be the basis of any civil or criminal liability because of the health care provider’s failure to comply with the requirements of this section.
This language still provides arguably too broad immunity to health care providers. However, it does not foreclose the consideration of a violation of the bill’s requirements, at least in criminal and civil proceedings. Rather, the language provides that a violation of the bill’s screening requirement itself cannot be the “basis” of civil or criminal liability on the part of the provider.
Given that the bill provides virtually no consequences for a health provider’s failure to comply with the bill’s screening mandate, and arguably has negative public policy outcomes by including the immunity provision – even as recently amended –the author may wish to consider, as the bill moves forward, making the bill explicitly discretionary (which it effectively is, given that its mandate is unenforceable) and removing the immunity provision from the bill.
ARGUMENTS IN SUPPORT: Altura Centers for Health (ACH) supports this bill and states despite the growing prevalence of Valley fever, awareness remains low. Misdiagnosis is common, leading to delay in treatment and unnecessary suffering for patients. ACH continues that public health agencies face significant challenges in tracking cases due to inconsistent testing and reporting practices. ACH continues that in the Central Valley, thousands of cases go unreported each year, leaving public health officials with an incomplete picture of the disease’s true impact. ACH contends that as Valley fever becomes more widespread, the need for improved surveillance, education, and research into its management requires the upmost urgency. ACH notes that the threat of Valley fever isn’t merely a problem for today, but it’s a looming problem for the future. Proactive measures like this bill aim to tackle this issue by requiring DPH to identify and share data on regions with high Valley fever rates, mandating screening in high-incidence areas when medically necessary, and ensuring health insurance providers, including Medi-Cal, cover screenings at no additional cost to patients.
ARGUMENTS IN OPPOSITION: The California Association of Health Plans (CAHP) and the Association of California Life and Health Insurance Companies (ACLHIC) write that they oppose SB 297, among others that mandate insurance coverage, as a matter of principle:
Large employers, unions, small businesses, and hard-working families value their ability to shop for the right health plan – at the right price – that best fits their needs. Benefit mandates impose a one-size-fits-all approach to medical care and benefit design without consideration for consumer choice. These bills will lead to higher premiums, harming health care affordability and access for small businesses and individuals.
State mandates increase premium costs for families, individuals, and small business owners who cannot or do not wish to self-insure.
The County Health Executives Association of California (CHEAC), representing local health departments, writes that they are opposed to the bill, unless amended to provide a funding source for the bill:
Local health departments share Senator Hurtado’s desire to ensure awareness and timely treatment for those with Valley Fever infections, many of whom live in underserved areas. However, the new mandate on local health departments to conduct Valley Fever outreach and education without funding for these activities unfortunately requires CHEAC to oppose SB 297 unless amended to address funding for the bill’s new local mandate.
REGISTERED SUPPORT / OPPOSITION:
Support
Altura Centers for Health
Aria Community Health Center
California Health Collaborative
Center on Race, Poverty & the Environment
City of Avenal
Kern Medical
Mycare Foundation
Saint Agnes Medical Center
Sierra View Medical Center
Southern California Contractors Association
Valley Fever Americas Foundation
One individual
Opposition
Association of California Life & Health Insurance Companies (ACLHIC)
California Association of Health Plans (CAHP)
County Health Executives Association of California (CHEAC) (unless amended)
Analysis Prepared by: Alison Merrilees / JUD. / (916) 319-2334
Date of Hearing: July 1, 2025
ASSEMBLY COMMITTEE ON HEALTH
Mia Bonta, Chair
SBPCA Bill Id:SB 297
Author:(Hurtado) – As Amended Ver:April 10, 2025
SENATE VOTE: 37-0
SUBJECT: Valley fever Screening and Prevention Act of 2025.
SUMMARY: Requires the California Department of Public Health (DPH) to annually analyze and identify regions with high rates of Valley fever and to publish a list of high-incidence regions. Requires Local Health Departments (LHDs) in high-incidence regions to ensure compliance with screening protocols for Valley fever. Requires LHDs to conduct outreach to health care providers and the general public to raise awareness of Valley fever risks, symptoms, and prevention strategies. Requires an adult patient receiving primary care services in a high incidence region to be offered a Valley fever screening test. Requires health plans, insurers, and Medi-Cal to cover Valley fever screening tests in high-incidence regions. Specifically, this bill:
- Requires DPH to annually analyze and identify regions with high rates of Valley fever using public health surveillance data.
- Require DPH to publish its first list of high-incidence regions for Valley fever on or before March 1, 2027.
- Requires DPH to provide LHDs in high-incidence regions with detailed infection data and standardized screening protocols for Valley fever.
- Required DPH to develop and distribute evidence-based training materials on Valley fever detection, diagnosis, and treatment for healthcare providers.
- Require DPH, on or before January 1, 2030, and every 2 years thereafter, to evaluate the effectiveness of the Valley fever screening and prevention program and report its findings to the Legislature in compliance with 10) of existing law below.
- Requires LHDs in high-incidence areas to conduct outreach to health care providers and the general public to raise awareness of Valley fever risks, symptoms, and prevention strategies.
- Requires LHDs to annually report the number of confirmed cases of Valley fever.
- Requires an adult patient receiving primary care services in a facility, clinic, unlicensed clinic, center, office, or other setting, and in a high-incidence region for Valley fever, to be offered a Valley fever screening test, to the extent these services are covered under the patient’s health insurance, based on the latest screening indications recommended by the latest national clinical practice guidelines, unless the health care provider reasonably believes that one of the following conditions applies:
- The patient is being treated for a life-threatening emergency.
- The patient has previously been offered or has been the subject of a Valley fever screening test, unless the health care provider determines that the screening test should be offered again.
- The patient lacks capacity to consent to a Valley fever screening test.
- The patient is being treated in the emergency department of a general acute care hospital.
- Requires, if a patient accepts the offer of a Valley fever screening test and the test result is positive, a health care provider to offer the patient followup health care or refer the patient to a health care provider who can provide followup health care.
- Requires follow-up health care to include diagnostic testing and care based on the latest national clinical practice guidelines recommended for Valley fever management.
- Requires the offering of a Valley fever screening test under this section shall be culturally and linguistically appropriate.
- Prohibits this bill from affecting the scope of practice of any health care provider or diminish any authority or legal or professional obligation of any health care provider to offer a Valley fever screening test, or to provide services or care for the patient of a Valley fever screening test.
- Prohibits a health care provider who fails to comply with these provisions from being subject to any disciplinary action related to their licensure or certification, or to any civil or criminal liability for that failure.
- Requires a health care service plan contract or health insurance policy, except for a specialized health insurance policy, that is issued, amended, delivered, or renewed on or after June 1, 2027, to cover a Valley fever screening test in high-incidence regions for Valley fever, as identified by DPH.
- Prohibits a health insurance policy from imposing a deductible, coinsurance, copayment, or any other cost-sharing requirement on the coverage provided pursuant to 10) above.
- Prohibits, notwithstanding 11), if a health insurance policy is a high deductible health plan, as defined in federal law the policy from imposing cost-sharing on a Valley fever screening test, unless not applying the cost sharing would conflict with federal requirements for high deductible health plans.
- Requires, commencing June 1, 2027, Valley fever screening tests in high-incidence regions for Valley fever, as identified by DPH, to be a Medi-Cal covered benefit, subject to any necessary federal approvals and federal financial participation.
- Defines, for purposes of this bill, the following:
- “Followup health care” to include providing medical management for Valley fever according to the latest national clinical practice guidelines.
- “Valley fever screening test” to include any laboratory test or tests that detect the presence of Coccidioides infection and provides confirmation of whether the patient has been infected.
- Makes the following findings and declarations:
- Valley fever is a significant public health concern in California, disproportionately impacting residents of arid regions.
- Early detection and intervention are essential to reduce the medical and economic burdens associated with severe cases of Valley fever.
- Valley fever screening and prevention is necessary to protect the health and well-being of Californians residing in high-risk areas.
EXISTING LAW:
- Establishes DPH, directed by a state Public Health Officer (PHO), to be vested with all the duties, powers, purposes, functions, responsibilities, and jurisdictions as they relate to public health and licensing of health facilities, as specified. [Health and Safety Code (HSC) § 131050]
- Requires each county board of supervisors to appoint a local health officer (LHO). [HSC § 101000]
- Requires LHOs to enforce and observe orders and ordinances of the board of supervisors, pertaining to the public health and sanitary matters, orders, including quarantine and other regulations prescribed by DPH, and statutes relating to public health. [HSC § 101030]
- Requires DPH to establish a list of diseases and conditions to be reported to DPH by LHOs, clinical laboratories, and health care providers, including Valley fever. [HSC § 120130 and 17 California Code of Regulations (CCR) § 2500, et seq.]
- Requires DPH to specify the timeliness requirements related to the reporting of each disease and condition, and the mechanisms required for, and the content to be included in, these reports. [HSC § 120130]
- Places reporting requirements on DPH related to Valley fever surveillance, including: attributing late-reported data to the year of diagnosis in future data reporting; collecting cases by April 15 of each year; reporting to LHOs about any removal of discrepant data; and, including an explanation for likely data changes between initial and final publication of data and an explanation for discrepancies. [HSC §§ 120161-120163]
- Establishes the Department of Managed Health Care (DMHC) to regulate health plans under the Knox-Keene Health Care Service Plan Act of 1975. [HSC § 1340, et seq.]
- Establishes the California Department of Insurance (CDI) to regulate health insurers. [INS § 106, et seq.]
- Establishes the Medi-Cal program, which is administered by the Department of Health Care Services (DHCS), and under which qualified low-income individuals receive health care services. [WIC § 14000, et seq.]
- Requires any report required or requested by law, or identified in the Legislative Analyst’s Supplemental Report of the Budget Act, to be submitted by a state or local agency to a committee of the Legislature or the Members of either house of the Legislature generally, to instead be submitted as a printed copy to the Secretary of the Senate, as an electronic copy to the Chief Clerk of the Assembly, and as an electronic or printed copy to the Legislative Counsel. Each report shall include a summary of its contents, not to exceed one page in length. Requires, if the report is submitted by a state agency, that agency to also provide an electronic copy of the summary directly to each member of the appropriate house or houses of the Legislature. Requires notice of receipt of the report to also be recorded in the journal of the appropriate house or houses of the Legislature by the secretary or clerk of that house. [Government Code § 9795]
- Defines “high deductible health plan” to means a health plan— (i) which has an annual deductible which is not less than— (I) $1,000 for self-only coverage, and (II) twice the dollar amount in subclause (I) for family coverage, and (ii) the sum of the annual deductible and the other annual out-of-pocket expenses required to be paid under the plan (other than for premiums) for covered benefits does not exceed— (I) $5,000 for self-only coverage, and (II) twice the dollar amount in subclause (I) for family coverage, as specified. [26 United States Code § 223(c)(2)]
FISCAL EFFECT: According to the Senate Appropriations Committee, unknown ongoing General Fund (GF) costs, likely hundreds of thousands, for DPH for state administration. The DMHC estimates minor and absorbable costs for state operations. CDI estimates costs of $6,000 in 2025-26 for state operations (Insurance Fund). Unknown, potential costs in the Medi-Cal program to the extent that additional outreach and test offerings result in increased utilization of Valley fever screening tests (GF and federal funds). Unknown, potential GF costs to reimburse county health departments for outreach activities. Cost to counties would be potentially reimbursable by the state, subject to a determination by the Commission on State Mandates.
COMMENTS:
- PURPOSE OF THIS BILL. According to the author, Valley fever is a growing public health crisis, yet too many cases go undiagnosed for too long. The author states that this bill ensures that Californians in high-incidence regions receive the early detection and care they deserve. The author notes that by 2027, DPH will identify the hardest-hit areas, giving communities the data they need to act. County health departments will standardize screening protocols and work with LHOs to educate providers and the public. The author contends that for too many, a simple test could mean the difference between a quick recovery and years of misdiagnosis. That’s why, starting in 2028, primary care providers in high-risk regions must offer Valley fever screenings to adults. No one should have to choose between affordability and their health—so beginning in 2027, insurance plans, including Medi-Cal (pending federal approval), will cover these tests without cost-sharing. The author states that public health should be proactive, not reactive. The author continues that this bill strengthens California’s response by requiring ongoing program assessments and legislative reports to ensure effectiveness. By equipping communities with better data, removing cost barriers, and prioritizing early detection, this bill takes a critical step toward reducing the devastating impact of Valley fever. The author concludes that Californians deserve a healthcare system that catches Valley fever early—before it catches them.
- BACKGROUND.
- What is Valley fever? Valley fever (also called coccidioidomycosis or “cocci”) is a disease caused by the Coccidioides fungus that grows in the soil and dirt in some areas of California and the southwestern United States. This fungus can infect the lungs and cause respiratory symptoms, including cough, difficulty breathing, fever, and tiredness or fatigue. In rare cases, the Valley fever fungus can spread to other parts of the body and cause severe disease – this type of Valley fever is less common and is called disseminated Valley fever. Valley fever can be serious and even fatal. People can get Valley fever by breathing in dust from outdoor air that contains spores of the Coccidioides fungus that grows in the soil. Like seeds from a plant, a fungus grows and spreads from tiny spores that are too small to see. When soil or dirt is stirred up by strong winds or while digging, dust containing these fungus spores can get into the air. Anyone who lives, works, or travels in an area where the Valley fever fungus grows can breathe in these fungus spores from outdoor dust without knowing it and become infected. Valley fever is not contagious, meaning it cannot spread from one person or animal to another.
- Prevalence of Valley fever. In California, the number of reported Valley fever cases has greatly increased in recent years. Since 2000, the number of cases has increased from less than 1,000 cases to more than 9,000 cases in 2019. According to DPH, most cases of Valley fever in California are reported from the Central Valley and Central Coast regions of the state, but the number of cases has also been increasing nearby in the northern Central Valley and southern coastal areas of California. From 2000-2018, the California Southern San Joaquin Central Valley region had the highest rates of Valley fever. Counties in this region include: Fresno; Kern; Kings; Madera; and Tulare. The California Central Coast and Northern San Joaquin Central Valley regions had increasing rates of Valley fever. Counties in these regions include: Monterey; San Luis Obispo; Santa Barbara; Ventura; Merced; San Benito; San Joaquin; Stanislaus. People are more likely to get Valley fever if they live, work, or travel in these areas or travel to other places where Valley fever has been reported, including nearby southwestern states, Mexico, and Central and South America.
- Reporting of Valley fever. Under state law, Valley fever is a reportable condition. Health care providers report suspected and confirmed cases to LHDs. LHDs are then mandated to report all cases of Valley fever to DPH. DPH uses data on Valley fever cases to track trends and better understand who is affected by Valley fever. DPH currently provides two types of surveillance updates on reported Valley fever cases in California: (1) provisional monthly updates and (2) final year-end updates. Data is provided in dashboard and report formats. DPH also periodically publishes more focused Valley fever reports in journals, including surveillance summaries, analyses of hospital and death data, and reports summarizing Valley fever outbreaks. AB 1790 (Salas and Grayson), Chapter 338, Statutes of 2018, provided resources for DPH to create a Valley fever awareness campaign to communicate with local health jurisdictions, healthcare providers, and the public about Valley fever, which it carried out from 2019 to 2020. This bill requires DPH to annually analyze and identify regions with high rates of Valley fever using public health surveillance data, publish its first list of high-incidence regions for Valley fever on or before March 1, 2027, provide LHDs in high-incidence regions with detailed infection data and standardized screening protocols for Valley fever.
- Valley fever and healthcare providers. DPH’s webpage titled “Information for Health Professionals” includes information about Valley fever, including but not limited to a DPH-issued health advisory warning healthcare providers about an increased number of reported cases of Valley fever and a recommendation that providers consider testing patients who present with compatible symptoms and risk factors, and other recommendations and guidance related to clinical testing and treatment. DPH’s website includes information about the federal Centers for Disease Control and Prevention (CDC)’s clinical testing algorithm for Valley fever. The CDC recommends the consideration of testing on an initial presentation of community-acquired pneumonia or erythema nodosum (an inflammatory disorder characterized by tender bumps under the skin) following recent respiratory symptoms for patients who: have a link to a known outbreak; or, live in or recently traveled to the highly endemic regions (like desert regions of South-Central Arizona and the San Joaquin Valley of California). The CDC also recommends testing in patients with community-acquired pneumonia who live in or recently traveled to an endemic area and have symptoms that did not improve following antibiotics. This bill includes a provision to develop and distribute evidence-based training materials on Valley fever detection, diagnosis, and treatment for health care providers. The author notes that the intent of this provision is to codify DPH’s existing practice. As it relates to providers, this bill requires adult patients receiving primary care services in a high incidence region for Valley fever to be offered testing to the extent the services are covered under the patient’s health insurance and based on the latest screening indications recommended by the latest national clinical practice guidelines. This bill prohibits a provider who fails to comply with the requirements of this bill from being subject to disciplinary actions related to their license or certification or any civil or criminal liability because of their failure to comply.
- Insurance coverage. This bill requires a health care service plan contract or health insurance policy, except as specified, that is issued, amended, delivered, or renewed on or after June 1, 2027, to cover, without cost sharing, Valley fever screening test, as specified, in high-incidence regions for Valley fever, as identified by DPH. According to information provided by DMHC, in general, medically necessary screenings are already covered benefits. Under DMHC regulations, “preventive health services” (including services for the detection of asymptomatic disease) include reasonable health appraisal examinations on a periodic basis. According to DMHC, Valley fever screenings are covered as medically necessary, subject to applicable cost sharing. State statute requires health plans to cover screenings recommended by the United States Preventive Services Task Force (USPSTF) without cost sharing. Currently, the USPSTF does not recommend Valley fever screenings. Thus, current law does not require these screenings without cost sharing. The author’s intent is to ensure Valley fever screenings for patients in high incidence areas are covered without cost sharing.
- Medi-Cal. According to information provided by DHCS, under existing Medi-Cal coverage, skin test screenings for Valley fever are available to Medi-Cal members as part of an office visit for any Medi-Cal member experiencing symptoms. In addition, Medi-Cal covers diagnostic blood tests. The screening skin test is covered as part of an office visit. The diagnostic blood test is covered as a lab service. Valley fever screenings skin tests are not separately reimbursed and are billed as part of an office visit. The fee-for-service (FFS) reimbursement rate for the diagnostic blood test is $11.62. Both the skin test and the blood test are available to Medi-Cal members statewide whenever a provider believes it’s medically necessary.
- SUPPORT. Altura Centers for Health (ACH) supports this bill and states despite the growing prevalence of Valley fever, awareness remains low. Misdiagnosis is common, leading to delay in treatment and unnecessary suffering for patients. ACH continues that public health agencies face significant challenges in tracking cases due to inconsistent testing and reporting practices. ACH continues that in the Central Valley, thousands of cases go unreported each year, leaving public health officials with an incomplete picture of the disease’s true impact. ACH contends that as Valley fever becomes more widespread, the need for improved surveillance, education, and research into its management requires the upmost urgency. ACH notes that the threat of Valley fever isn’t merely a problem for today, but it’s a looming problem for the future. Proactive measures like this bill aim to tackle this issue by requiring DPH to identify and share data on regions with high Valley fever rates, mandating screening in high-incidence areas when medically necessary, and ensuring health insurance providers, including Medi-Cal, cover screenings at no additional cost to patients.
- OPPOSITION. The California Medical Association (CMA) opposes a mandate requiring physicians to offer Valley fever testing to all primary care patients in high-incidence regions. CMA continues that the mandate overrides a physician’s clinical judgment in determining whether testing is appropriate for a given patient. For context, Valley fever is typically a mild infection for most individuals, with 90% to 95% of those infected experiencing mild symptoms that resolve without testing or treatment. CMA continues that mandating physicians to offer this testing would result in unnecessary screenings for asymptomatic individuals or those with mild symptoms, even when offering the test goes against clinical judgment. CMA contends that this could contribute to longer wait times for all patients awaiting laboratory results – a serious concern, particularly for those with severe Valley fever symptoms or for those experiencing other health issues where timely testing is essential to their recovery. CMA argues that unlike other conditions such as Tuberculosis, Valley fever currently lacks a risk assessment tool, making clinical discretion even more crucial. CMA concludes that it’s critical that we not remove a physician’s clinical judgement to offer Valley fever testing to patients in high-incidence regions, as appropriate.
- OPPOSE UNLESS AMENDED. The County Health Executives Association of California (CHEAC) opposes this bill unless it is amended and states, LHDs are already required to report all positive Valley fever cases to DPH, and several jurisdictions with higher case counts coordinate outreach to providers and the public on the conditions, symptoms, and causes of Valley fever, to the extent resources allow. However, there is currently no dedicated funding for these activities, and this bill does not provide funding to carry out this new mandate. CHEAC appreciates the author’s willingness to limit the new mandate for outreach and education to “high incidence area” as defined in the bill, but respectfully requests the insertion of “upon appropriation” or “to the extent that resources are available”. CHEAC notes that LHDs are facing the elimination of vital federal funding and deep cuts to core public health programs. Considering this context, policymakers have a duty to ensure that new mandates are paired with adequate funding. LHDs share the author’s desire to ensure awareness and timely treatment for those with Valley fever infections, many of whom live in underserved areas. However, the new mandate on LHDs to conduct Valley fever outreach and education without funding for these activities requires CHEAC to oppose this bill unless amended to address this concern.
- PREVIOUS LEGISLATION.
- SB 1231 (Caballero) of 2022 would have required DPH to create a California Standard Diagnostic for Valley fever and to conduct an awareness campaign to communicate with LHDs, providers, and the public about the Diagnostic for Valley fever. SB 1231 was held on the Assembly Appropriations Committee suspense file.
- AB 789 (Low), Chapter 470, Statutes of 2021 requires an adult patient who receives primary care services to be offered a hepatitis B and C screening test according to the latest recommendations from the USPSTF, and to the extent these services are covered under the patient's health insurance, unless the patient lacks capacity to consent to the test, or is being treated in the emergency department of a general acute care hospital.
- AB 1787 (Salas and Fong), Chapter 229, Statutes of 2018 places reporting requirements on DPH related to Valley fever surveillance, including: attributing late-reported data to the year of diagnosis in future data reporting; collecting cases by April 15 of each year; reporting to LHOs about any removal of discrepant data; and including an explanation for likely data changes between initial and final publication of data, and an explanation for discrepancies between data reported by an LHO and data reported by DPH.
- AB 1788 (Salas and Grayson), Chapter 230, Statutes of 2018 permits DPH, for the purpose of Valley fever case reports, to use a laboratory criteria for diagnosis, with or without clinical criteria.
- AB 1789 (Salas and Fong) of 2018 would have required the Occupational Safety and Health Standards Board to adopt Valley fever standards for state public works projects, as specified. AB 1789 was held on the Assembly Committee of Appropriations suspense file.
- AB 1790 (Salas and Grayson), Chapter 338, Statutes of 2018, enacted the Valley fever Education, Early Diagnosis, and Treatment Act, and required DPH to conduct an awareness campaign to LHDs, providers, and the public. AB 1790 became inoperative on January 1, 2021.
- AB 1279 (Salas) of 2017 would have required DPH to develop and implement public outreach programs to educate the public about Valley fever. AB 1279 was vetoed by Governor Brown, who stated: “DPH already provides fact sheets, brochures, posters and other educational materials to raise awareness of this disease. Expanding this program would necessitate additional resources which should be considered along with other funding requests as part of the budget process.”
- AMENDMENTS (TO BE TAKEN IN A SUBSEQUENT COMMITTEE). In consultation with the committee, the author has committed to address stakeholder concerns regarding maintaining a physician’s clinical judgment to offer Valley fever testing to patients in high-incidence regions, as appropriate, by amending this bill to require culturally and linguistically appropriate screening for valley fever. Given that Valley fever screenings and tests are already covered under Medi-Cal, the author has also committed to striking the current Medi-Cal provisions and including a finding and declaration to the effect that Valley fever screenings and tests are covered. Given that that Valley fever testing is covered subject to applicable cost sharing, the author has committed to amending this bill to clarify that this bill requires health plans to cover Valley fever screening tests without cost sharing for any covered individual who lives, works, goes to school, or has recently visited a region with a high incidence of Valley fever. The author has also committed to an amendment requiring DPH to annually analyze and identify regions with high rates of Valley fever to the extent feasible using available data and resources based on public health surveillance data in consultation with subject matter experts. The amendments would additionally authorize DPH to revise its identification criteria over time in response to shifting patterns of disease incidence. Because this bill is double referred, and due to timing issues, amendments will be taken in a subsequent committee.
- DOUBLE REFERRAL. This bill is double referred. Should the bill pass out of this committee, it will be referred to the Assembly Committee on Judiciary.
REGISTERED SUPPORT / OPPOSITION:
Support
Altura Centers for Health
Aria Community Health Center
California Health Collaborative
City of Avenal
Kern Medical
Mycare Foundation
Saint Agnes Medical Center
One individual
Opposition
California Medical Association (CMA)
Analysis Prepared by: Eliza Brooks / HEALTH / (916) 319-2097
SENATE RULES COMMITTEE Office of Senate Floor Analyses (916) 651-1520 Fax: (916) 327-4478 | SB 297 |
THIRD READING
Bill No: SB 297
Author: Hurtado (D)
Amended: 4/10/25
Vote: 21
SENATE HEALTH COMMITTEE: 10-0, 4/9/25
AYES: Menjivar, Valladares, Durazo, Gonzalez, Grove, Limón, Padilla, Richardson, Rubio, Wiener
NO VOTE RECORDED: Weber Pierson
SENATE JUDICIARY COMMITTEE: 12-0, 4/29/25
AYES: Umberg, Niello, Allen, Arreguín, Ashby, Caballero, Durazo, Laird, Stern, Valladares, Wahab, Wiener
NO VOTE RECORDED: Weber Pierson
SENATE APPROPRIATIONS COMMITTEE: 6-0, 5/23/25
AYES: Caballero, Seyarto, Cabaldon, Grayson, Richardson, Wahab
NO VOTE RECORDED: Dahle
SUBJECT: Valley Fever Screening and Prevention Act of 2025
SOURCE: Author
DIGEST:
This bill (1) requires the California Department of Public Health to annually analyze and identify regions with high rates of Valley Fever and to publish a list of high-incidence regions. (2) Requires local health departments (LHDs) in high incidence areas to conduct outreach to health care providers and the general public to raise awareness of Valley Fever risks, symptoms, and prevention strategies. (3) Requires an adult patient receiving primary care services in a high incidence region to be offered a Valley Fever screening test. (4) Requires health plans, insurers, and Medi-Cal to cover Valley Fever screening tests in high-incidence regions.
ANALYSIS:
Existing law:
- Establishes the California Department of Public Health (CDPH), directed by a state Public Health Officer (PHO), to be vested with all the duties, powers, purposes, functions, responsibilities, and jurisdictions as they relate to public health and licensing of health facilities, as specified. Gives the PHO broad authority to detect, monitor, and prevent the spread of communicable disease in the state. [Health and Safety Code (HSC) §131050 and §120130]
- Requires each county board of supervisors to appoint a local health officer (LHO). Requires LHOs to enforce and observe orders and ordinances of the board of supervisors, pertaining to the public health and sanitary matters, orders, including quarantine and other regulations prescribed by CDPH, and statutes relating to public health. [HSC §101000 and §101030]
- Requires CDPH to establish a list of diseases and conditions to be reported to CDPH by LHOs, clinical laboratories, and health care providers (Valley Fever is on this list). Requires CDPH to specify the timeliness requirements related to the reporting of each disease and condition, and the mechanisms required for, and the content to be included in, these reports. [HSC §120130 and 17 CCR §2500, et seq.]
- Places reporting requirements on CDPH related to Valley Fever surveillance, including: attributing late-reported data to the year of diagnosis in future data reporting; collecting cases by April 15 of each year; reporting to LHOs about any removal of discrepant data; and, including an explanation for likely data changes between initial and final publication of data and an explanation for discrepancies. [HSC §120161, §120162 and §120163]
- Establishes the Department of Managed Health Care to regulate health plans under the Knox-Keene Health Care Service Plan Act of 1975 and the California Department of Insurance to regulate health insurers. Establishes the Medi-Cal program, which is administered by the Department of Health Care Services, and under which qualified low-income individuals receive health care services. [HSC §1340, et seq., Insurance Code (INS) §106, et seq. and Welfare and Institutions Code (WIC) §14000, et seq.]
This bill:
- Requires CDPH to annually analyze and identify regions with high rates of Valley Fever using public health surveillance data. Requires CDPH to publish its first list of high-incidence regions for Valley Fever by March 1, 2027.
- Requires CDPH to provide LHDs in high-incidence regions with detailed infection data and standardized screening protocols for Valley Fever.
- Requires CDPH to develop and distribute evidence-based training materials on Valley Fever detection, diagnosis, and treatment for health care providers.
- Requires LHDs in high-incidence regions to conduct outreach to health care providers and the general public to raise awareness of Valley Fever risks, symptoms, and prevention strategies.
- Requires LHDs to annually report to CDPH, including the confirmed cases of Valley Fever.
- Requires, beginning January 1, 2028, an adult patient who receives primary care services in a facility, clinic, unlicensed clinic, center, office, or other setting where primary care services are provided, and in an identified high-incidence region for Valley Fever, to be offered a Valley Fever screening test, to the extent these services are covered under the patient’s health insurance, based on the latest screening indications recommended by the latest national clinical practice guidelines, unless the health care provider reasonably believes that one of the following conditions applies:
- The patient is being treated for a life-threatening emergency;
- The patient has previously been offered or has been the subject of a Valley Fever screening test, unless the health care provider determines that the screening test should be offered again;
- The patient lacks capacity to consent to a Valley Fever screening test; or
- The patient is being treated in an emergency department.
- Requires the offering of a Valley Fever screening test to be culturally and linguistically appropriate.
- Requires a health care provider, if a patient accepts the offer of a Valley Fever screening test and the test result is positive, to offer the patient follow-up health care or refer the patient to a health care provider who can provide follow-up health care. Requires follow-up health care to include diagnostic testing and care based on the latest national clinical practice guidelines recommended for Valley Fever management.
- Prohibits this bill from affecting the scope of practice of any health care provider or diminish any authority or legal or professional obligation of any health care provider to offer a Valley Fever screening test, or to provide services or care for the patient of a Valley Fever screening test. Prohibits a health care provider that fails to comply with these requirements of this bill from being subject to any disciplinary actions related to their licensure or certification, or to any civil or criminal liability, because of the health care provider’s failure to comply.
- Requires health plans, insurers, and Medi-Cal, after June 1, 2027, to cover Valley Fever screening tests in high-incidence regions. Prohibits deductibles, coinsurance, copayments, or any other cost-sharing requirement on this coverage. Requires the Medi-Cal mandate to be implemented only to the extent that any necessary federal approvals are obtained and federal financial participation is available and not otherwise jeopardized.
- Requires CDPH, by January 1, 2030 and every two years thereafter, to evaluate the effectiveness of the Valley Fever screening and prevention program and report its findings to the Legislature.
Comments
According to the author of this bill:
Valley Fever is a growing public health crisis, yet too many cases go undiagnosed for too long. This bill ensures that Californians in high-incidence regions receive the early detection and care they deserve. By 2027, CDPH will identify the hardest-hit areas, giving communities the data they need to act. County health departments will standardize screening protocols and work with local health officers to educate providers and the public. For too many, a simple test could mean the difference between a quick recovery and years of misdiagnosis. That’s why, starting in 2028, primary care providers in high-risk regions must offer Valley Fever screenings to adults. No one should have to choose between affordability and their health—so beginning in 2027, insurance plans, including Medi-Cal (pending federal approval), will cover these tests without cost-sharing. Public health should be proactive, not reactive. This bill strengthens California’s response by requiring ongoing program assessments and legislative reports to ensure effectiveness. By equipping communities with better data, removing cost barriers, and prioritizing early detection, this bill takes a critical step toward reducing the devastating impact of Valley Fever. Californians deserve a healthcare system that catches Valley Fever early—before it catches them.
Background
According to the Centers for Disease Control and Prevention (CDC), Valley Fever is an infection caused by the fungus coccidioides. The fungus lives in the soil in the southwestern U.S., south-central Washington state, and parts of Mexico and Central and South America. People can get Valley Fever by breathing in microscopic coccidioides spores from the air, although some people never get sick from it. It does not spread from person-to-person or between people and animals. Valley Fever is detected through blood or skin tests and causes typical lung infection symptoms, like cough and fever. Certain groups of people may be at higher risk for developing the severe forms of Valley Fever, such as: people with weakened immune systems, pregnant women, people who have diabetes, those over 60, and Black or Filipino people. The CDC states that many people get better without medication within a few months, but antifungal medications is prescribed for people with more serious infections or those with risk factors for severe infection. Because Valley Fever has the same symptoms as pneumonias, it is often misdiagnosed or undiagnosed, which can lead to ineffective treatments or delays in treatment.
In 2022, there were 17,612 reported cases of Valley Fever in the U.S., with 7,459 of those in California. According to the CDC, rates are highest among people 60 years and older. On average, there were approximately 200 Valley Fever-associated deaths each year from 1999 to 2021. The number of Valley Fever cases reported likely underestimates the true number of cases, and tens of thousands more illnesses likely occur because many patients are not tested for Valley fever. In highly endemic areas such as the Phoenix and Tucson metropolitan areas, Valley Fever causes an estimated 15% to 30% of community-acquired pneumonias.
UC Berkeley study. A UC Berkeley study published in March 2025 in the Journal of the Royal Society Interface found that longer, drier summers in California can extend the transmission season of Valley Fever. The study finds that shifts in seasonal rainfall patterns (like those anticipated with climate change) shift the start of the transmission season earlier and prolong its duration. Researchers analyzed historical Valley Fever case data alongside climate records to examine how temperature and precipitation patterns impact the timing and duration of transmission seasons. Their findings suggest that drier springs accelerate the onset of transmission seasons and drier falls delay the end of the transmission season. The study’s principal investigator stated that “healthcare providers should be especially vigilant during and following prolonged dry seasons, as these periods may correspond with heightened disease transmission.”
CDC testing recommendations. According to the CDC, Valley Fever cannot be reliably distinguished from other causes of respiratory illness by signs or symptoms alone. The CDC recommends the consideration of testing on an initial presentation of community-acquired pneumonia or erythema nodosum (an inflammatory disorder characterized by tender bumps under the skin) following recent respiratory symptoms who: have a link to known outbreak; or, who live in or recently traveled to the highly endemic regions (like desert regions of South-Central Arizona and the San Joaquin Valley of California). The CDC also recommends testing in patients with community-acquired pneumonia who live in or recently traveled to an endemic area and have symptoms that did not improve following antibiotics.
FISCAL EFFECT: Appropriation: No Fiscal Com.: Yes Local: Yes
According to the Senate Appropriations Committee:
- Unknown ongoing General Fund costs, likely hundreds of thousands, for CDPH for state administration.
- DMHC estimates minor and absorbable costs for state operations.
- CDI estimates costs of $6,000 in 2025-26 for state operations (Insurance Fund).
- Unknown, potential costs in the Medi-Cal program to the extent that additional outreach and test offerings result in increased utilization of Valley Fever screening tests (General Fund and federal funds).
- Unknown, potential General Fund costs to reimburse county health departments for outreach activities. Cost to counties would be potentially reimbursable by the state, subject to a determination by the Commission on State Mandates.
SUPPORT: (Verified 5/23/2025)
Altura Centers for Health
Aria Community Health Center
California Health Collaborative
Center on Race, Poverty, & the Environment
City of Avenal
MyCare Foundation
Saint Agnes Medical Center
Valley Fever Americas Foundation
Valley Fever Institute at Kern Medicine
OPPOSITION: (Verified 5/23/2025)
California Medical Association
ARGUMENTS IN SUPPORT: Supporters write that farmworkers, construction crews, and other outdoor laborers are especially vulnerable to Valley Fever, as they may be unknowingly inhaling spores. Without proper testing and diagnosis, these individuals can suffer debilitating illness, miss work, and face mounting medical costs. Climate change is also contributing to Valley Fever’s rapid spread. Rising temperatures and prolonged droughts create conditions that allow coccidiodes fungus to thrive. As a result, communities and towns that have never before faced the threat of Valley Fever are becoming hotspots for the disease. Valley Fever is an urgent environmental justice issue for the communities in the southern San Joaquin Valley, which has historically experienced some of the highest infection rates in the country. There is evidence that communities of color (particularly Black and Filipino communities) and vulnerable populations (such as pregnant and immunocompromised people) are at higher risk of infection than the general population. Despite its growing prevalence, awareness of Valley Fever remains low. Misdiagnosis is common, leading to delay in treatment and unnecessary suffering for patients. Public health agencies face significant challenges in tracking cases due to inconsistent testing and reporting practices. In the San Joaquin Valley, thousands of cases go unreported each year, leaving public health officials with an incomplete picture of the disease’s true impact. The threat of Valley Fever will continue to grow and affect more communities as climate change creates more conditions for infection to spread. Proactive measures like this bill aim to tackle this issue by requiring the CDPH to identify and share data on regions with high Valley Fever rates, mandating screenings in high-incidence areas when medically necessary, and ensuring health insurance providers, including Medi-Cal, cover screenings at no additional cost to patients.
ARGUMENTS IN OPPOSITION: The California Medical Association (CMA) writes that they oppose a mandate requiring physicians to offer Valley Fever testing to all primary care patients in high-incidence regions. CMA states that this mandate overrides a physician’s clinical judgment in determining whether testing is appropriate for a given patient. For context, Valley Fever is typically a mild infection for most individuals, with 90% to 95% of those infected experiencing mild symptoms that resolve without testing or treatment. Only an estimated 5% to 10% of infected individuals experience worsening or severe symptoms requiring medical intervention, with those who have weakened immune systems or underlying health conditions being at the highest risk for developing severe symptoms. Additionally, mandating physicians to offer this testing would result in unnecessary screenings for asymptomatic individuals or those with mild symptoms, even when offering the test goes against clinical judgment. This could contribute to longer wait times for all patients awaiting laboratory results – a serious concern, particularly for those with severe Valley Fever symptoms or for those experiencing other health issues where timely testing is essential to their recovery.
Prepared by: Melanie Moreno / HEALTH / (916) 651-4111
5/26/25 13:06:31
**** END ****
SENATE COMMITTEE ON
Senator Anna Caballero, Chair
2025 - 2026 Regular Session
SB 297 (Hurtado) - Valley Fever Screening and Prevention Act of 2025
Version: | Policy Vote: |
Urgency: | Mandate: |
Hearing Date: | Consultant: |
Bill Summary:
SB 297 would require an adult patient who receives primary care services in a health care setting and in a high-incidence region for valley fever, to be offered a valley fever screening test, as specified.
Fiscal Impact:
- Unknown ongoing General Fund costs, likely hundreds of thousands, for the California Department of Public Health (CDPH) for state administration.
- The Department of Managed Health Care (DMHC) estimates minor and absorbable costs for state operations.
- The California Department of Insurance (CDI) estimates costs of $6,000 in 2025-26 for state operations (Insurance Fund).
- Unknown, potential costs in the Medi-Cal program to the extent that additional outreach and test offerings result in increased utilization of Valley Fever screening tests (General Fund and federal funds).
- Unknown, potential General Fund costs to reimburse county health departments for outreach activities. Cost to counties would be potentially reimbursable by the state, subject to a determination by the Commission on State Mandates.
Background:
According to the Centers for Disease Control and Prevention (CDC), Valley Fever is an infection caused by the fungus coccidioides. The fungus lives in the soil in the southwestern U.S., south-central Washington state, and parts of Mexico and Central and South America. People can get Valley Fever by breathing in microscopic coccidioides spores from the air, although some people never get sick. Valley Fever does not spread from person-to-person or between people and animals. Valley Fever is detected through blood or skin tests and causes typical lung infection symptoms, like cough and fever. Certain groups of people may be at higher risk for developing the severe forms of Valley Fever, such as: people with weakened immune systems, pregnant women, people who have diabetes, those over 60, and Black or Filipino people. The CDC states that many people get better without medication within a few months, but antifungal medications is prescribed for people with more serious infections or those with risk factors for severe infection.
According to the CDC, Valley Fever cannot be reliably distinguished from other causes of respiratory illness by signs or symptoms alone. The CDC recommends the consideration of testing on an initial presentation of community-acquired pneumonia or erythema nodosum (an inflammatory disorder characterized by tender bumps under the skin) following recent respiratory symptoms who have a link to known outbreak; or, who live in or recently traveled to the highly endemic regions (like desert regions of South-Central Arizona and the San Joaquin Valley of California). The CDC also recommends testing in patients with community-acquired pneumonia who live in or recently traveled to an endemic area and have symptoms that did not improve following antibiotics.
State law requires CDPH to establish a list of diseases and conditions (including Valley Fever) to be reported to CDPH by local health officers, clinical laboratories, and health care providers. Current law places reporting requirements on CDPH related to Valley Fever surveillance, including: attributing late-reported data to the year of diagnosis in future data reporting; collecting cases by April 15 of each year; reporting to local health officers about any removal of discrepant data; and, including an explanation for likely data changes and an explanation for discrepancies.
Proposed Law:
Specific provisions of the bill would:
- Require an adult patient who receives primary care services in a facility, clinic, unlicensed clinic, center, office, or other setting where primary care services are provided, and in a high-incidence region for valley fever, as specified, to be offered a valley fever screening test, to the extent these services are covered under the patient’s health insurance, based on the latest screening indications recommended by the latest national clinical practice guidelines, unless the health care provider reasonably believes that certain conditions apply.
- Require health plans and insurers to cover a valley fever screening test, pursuant to the above provision, in high-incidence regions for valley fever, as specified, and prohibit health plans and insurers from imposing a deductible, coinsurance, copayment, or any other cost-sharing requirement on this coverage.
- Require that valley fever screening tests in high-incidence regions for valley fever, as specified, be a covered benefit under the Medi-Cal program.
- Require CDPH to annually analyze and identify regions with high rates of valley fever using public health surveillance data; provide local health departments in high-incidence regions with detailed infection data and standardized screening protocols for valley fever; develop and distribute evidence-based training materials on valley fever detection, diagnosis, and treatment for health care providers; and evaluate the effectiveness of the valley fever screening and prevention program and report its findings to the Legislature, as specified.
- Require local health departments in high incidence areas to conduct outreach to health care providers and the general public to raise awareness of valley fever risks, symptoms, and prevention strategies; and annually report to the CDPH the number of confirmed cases of valley fever.
-- END --
Senator Thomas Umberg, Chair
2025-2026 Regular Session
Bill No: SB 297 (Author:Hurtado)
Version: April 10, 2025
Hearing Date: April 29, 2025
Fiscal: Yes
Urgency: No
Consultant: CK
SUBJECT
Valley fever Screening and Prevention Act of 2025
DIGEST
This bill requires an adult patient receiving primary care services in specified health care settings to be offered a valley fever screening test, if certain conditions apply, and followup care if the patient tests positive. The bill provides that no liability attaches for a health care provider’s failure to comply with these requirements.
EXECUTIVE SUMMARY
Valley fever is an invasive fungal disease that cannot be reliably distinguished from other causes of respiratory illness by signs or symptoms alone. It is commonly misdiagnosed and inappropriately treated. Valley fever affects approximately 10,000 to 20,000 people each year. Most of these reported cases occur in California and Arizona.
To respond to this increased incidence of valley fever in certain California communities, this bill requires patients to be offered valley fever screening tests based on screening indications recommended by the latest national clinical practice guidelines, to the extent these services are covered under the patient’s health insurance, and certain conditions are met. There are reporting requirements for state and local health entities and provisions related to health care coverage. Relevant to this Committee’s jurisdiction, no liability attaches for a health care provider’s violation of this bill’s provisions regarding screening tests.
This bill is author-sponsored. It is supported by the City of Avenal and various health care organizations, including the Kern Medical and Saint Agnes Medical Center. It is opposed by the California Medical Association and County Health Executives Association of California. This bill passed out of the Senate Health Committee on a vote of 10 to 0.
PROPOSED CHANGES TO THE LAW
Existing law:
- Provides that any person who violates specified portions of the Health and Safety Code, or who willfully or repeatedly violates any rule or regulation adopted thereunder, is guilty of a misdemeanor and upon conviction thereof shall be punished by a fine or by imprisonment, or by both the fine and imprisonment. (Health & Saf. Code § 1290.)
- Establishes the Department of Public Health (CDPH), directed by a state Public Health Officer (PHO), to be vested with all the duties, powers, purposes, functions, responsibilities, and jurisdiction as they relate to public health and licensing of health facilities, as specified. Gives the PHO broad authority to detect, monitor, and prevent the spread of communicable disease in the state. (Health & Saf. Code § 131050 and § 120130 et seq.)
- Exempts various types of clinics from licensure and regulation by CDPH, including any place or establishment owned or operated as a clinic or office by one or more licensed health care practitioners and used as an office for the practice of their profession, and any clinic operated as an outpatient department of a hospital. (Health & Saf. Code § 1206.)
- Requires every health care provider, knowing of or in attendance on a case or suspected case of a disease on the list of reportable diseases and conditions, to be reported as required to CDPH. (17 C.C.R. §§ 2500, 2593, 2641.5- 2643.20, and 2800-2812.)
- Requires an adult patient who receives primary care services in a facility, clinic, unlicensed clinic, center, office, or other setting where primary care services are provided, to be offered a hepatitis B screening test and a hepatitis C screening test, to the extent these services are covered under the patient’s health insurance, based on the latest screening indications recommended by the USPSTF, unless the health care provider reasonably believes that specified conditions apply, including that the patient is being treated for a life-threatening emergency or the patient lacks capacity to consent to such tests. (Health & Saf. Code § 1316.7.)
This bill:
- Provides, commencing January 1, 2028, that an adult patient who receives primary care services in a facility, clinic, unlicensed clinic, center, office, or other setting where primary care services are provided, and that is in a high-incidence region for valley fever, as identified by CDPH, shall be offered a valley fever screening test, to the extent these services are covered under the patient’s health insurance, based on the latest screening indications recommended by the latest national clinical practice guidelines, unless the health care provider reasonably believes that one of the following conditions applies:
- The patient is being treated for a life-threatening emergency.
- The patient has previously been offered or has been the subject of a valley fever screening test, unless the health care provider determines that it should be offered again.
- The patient lacks capacity to consent to the test.
- The patient is being treated in the emergency department of a general acute care hospital, as defined.
- Requires a health care provider, if a patient accepts the offer of the screening test and the test is positive, to offer the patient followup health care or refer the patient to a health care provider who can provide followup health care.
- Clarifies that it does not affect the scope of practice of any health care provider or diminish any authority or legal or professional obligation of any health care provider to offer a valley fever screening test, or to provide services or care for the patient of a valley fever screening test.
- Provides that a health care provider that fails to comply with these requirements shall not be subject to any disciplinary actions related to their licensure or certification, or to any civil or criminal liability, because of the health care provider’s failure to comply with these requirements.
- Requires CDPH to annually analyze and identify regions with high rates of valley fever using public health surveillance data. Requires CDPH to publish its first list of high-incidence regions for valley fever by March 1, 2027.
- Requires CDPH to provide (local health departments) LHDs in high-incidence regions with detailed infection data and standardized screening protocols for valley fever.
- Requires CDPH to develop and distribute evidence-based training materials on valley fever detection, diagnosis, and treatment for health care providers.
- Requires LHDs in high incidence areas to conduct outreach to health care providers and the general public to raise awareness of valley fever risks, symptoms, and prevention strategies.
- Requires LHDs to annually report to CDPH, including the confirmed cases of valley fever.
- Requires health plans, insurers, and Medi-Cal, after June 1, 2027, to cover valley fever screening tests in high-incidence regions. Prohibits deductibles, coinsurance, copayments, or any other cost-sharing requirement on this coverage, except as provided. Requires the Medi-Cal mandate to be implemented only to the extent that any necessary federal approvals are obtained and federal financial participation is available and not otherwise jeopardized.
- Requires CDPH, by January 1, 2030 and every two years thereafter, to evaluate the effectiveness of the valley fever screening and prevention program and report its findings to the Legislature.
COMMENTS
- Author’s comment
According to the author:
Valley fever is a growing public health crisis, yet too many cases go undiagnosed for too long. SB 297 ensures that Californians in high-incidence regions receive the early detection and care they deserve. By 2027, the California Department of Public Health will identify the hardest-hit areas, giving communities the data they need to act. County health departments will standardize screening protocols and work with local health officers to educate providers and the public.
For too many, a simple test could mean the difference between a quick recovery and years of misdiagnosis. That’s why, starting in 2028, primary care providers in high-risk regions must offer Valley fever screenings to adults. No one should have to choose between affordability and their health—so beginning in 2027, insurance plans, including Medi-Cal (pending federal approval), will cover these tests without cost-sharing.
Public health should be proactive, not reactive. SB 297 strengthens California’s response by requiring ongoing program assessments and legislative reports to ensure effectiveness. By equipping communities with better data, removing cost barriers, and prioritizing early detection, this bill takes a critical step toward reducing the devastating impact of Valley fever. Californians deserve a healthcare system that catches Valley fever early—before it catches them.
- This bill requires health care providers to offer valley fever screening tests under certain circumstances
According to the U.S. Centers for Disease Control and Prevention (CDC):
Coccidioidomycosis (Valley fever) is an invasive fungal disease that often presents as community-acquired pneumonia (CAP) in primary and urgent care settings. It is endemic in parts of the U.S. and the world.
Coccidioidomycosis cannot be reliably distinguished from other causes of respiratory illness by signs or symptoms alone. It is commonly misdiagnosed and inappropriately treated with antibiotics—up to 70% of patients may receive inappropriate antibacterial drugs. In highly endemic regions for coccidioidomycosis, erythema nodosum is commonly the presenting symptom.
Testing for coccidioidomycosis may be considered on the initial patient encounter or at a secondary visit, depending on situational factors.[1]
There are roughly 10,000 to 20,000 cases of valley fever reported to the CDC each year with most cases occurring in Arizona and California. From 2017 to 2022, California had roughly 7,000-9,000 cases.[2]
This bill, in relevant part, seeks to identify the incidence of valley fever in certain California communities and to get treatment for infected patients more systematically by requiring specified health facilities to provide valley fever screening tests to adult patients based on the latest screening indications recommended, and to provide followup care or referrals, as specified.
The goal is to expand the response to unidentified outbreaks, not to punish health care professionals. Therefore, the bill specifically provides that health care providers that fail to comply are not subject to any disciplinary actions related to their licensure or certification, or to any civil or criminal liability for such failure.
This approach closely models that carried out in AB 789 (Low, Ch. 470, Stats. 2021), which requires similar screenings at these facilities for hepatitis B and C, and AB 2132 (Low, Ch. 951, Stats. 2024), which requires such screenings for tuberculosis.
The bill also requires CDPH to annually analyze and identify regions with high rates of valley fever using public health surveillance data and to publish its first list of high-incidence regions for valley fever on or before March 1, 2027. CDPH must also provide LHDs in high-incidence regions with detailed infection data and standardized screening protocols.
LHDs in high incidence areas are required to conduct outreach to health care providers and the general public to raise awareness of valley fever risks, symptoms, and prevention strategies and to also annually report to CDPH the number of confirmed cases of valley fever.
- Stakeholder positions
The California Health Collaborative writes in support:
Climate change is also contributing to Valley fever’s rapid spread. Rising temperatures and prolonged droughts create conditions that allow Coccidioides fungus to thrive. As a result, communities and towns that have never before faced the threat of Valley fever are becoming hotspots for the disease. Valley fever is a persistent health challenge in the Western United States, particularly in California and Arizona, where the fungus thrives in hot and dry climates. Between 10,000 and 20,000 cases are reported annually in the United States. However, experts believe the true number is much higher due to under diagnosis. Valley fever has been found to affect many of the families our organization serves and would like to support in continuing to educate and prevent them from being exposed to Valley fever.
Despite its growing prevalence, awareness of Valley fever remains low. Misdiagnosis is common, leading to delay in treatment and unnecessary suffering for patients. Public health agencies face significant challenges in tracking cases due to inconsistent testing and reporting practices.
Saint Agnes Medical Center explains the need for the bill:
In the Central Valley, thousands of cases go unreported each year, leaving public health officials with an incomplete picture of the disease’s true impact. As Valley fever becomes more widespread, the need for improved surveillance, education, and research into its management requires the upmost urgency.
The threat of Valley fever isn’t merely a problem for today, but it’s a looming problem for the future. Proactive measures like SB 297 aim to tackle this issue by requiring the California Department of Public health to identify and share data on regions with high Valley fever rates, mandating screenings in high-incidence areas when medically necessary, and ensuring health insurance providers, including Medi-Cal, cover screenings at no additional cost to patients.
Writing in opposition, the California Medical Association argues:
While we appreciate and support the author’s intent to enhance early detection and treatment of Valley fever infections, CMA must oppose a mandate requiring physicians to offer Valley fever testing to all primary care patients in high-incidence regions. Unfortunately, this approach presents several concerns. First, this mandate overrides a physician’s clinical judgment in determining whether testing is appropriate for a given patient. For context, Valley fever is typically a mild infection for most individuals, with 90 to 95 percent of those infected experiencing mild symptoms that resolve without testing or treatment. Only an estimated 5 to 10 percent of infected individuals experience worsening or severe symptoms requiring medical intervention, with those who have weakened immune systems or underlying health conditions being at the highest risk for developing severe symptoms.
Additionally, mandating physicians to offer this testing would result in unnecessary screenings for asymptomatic individuals or those with mild symptoms, even when offering the test goes against clinical judgment.
SUPPORT
Altura Centers for Health
Aria Community Health Center
California Health Collaborative
City of Avenal
Kern Medical
Mycare Foundation
Saint Agnes Medical Center
OPPOSITION
California Medical Association
County Health Executives Association of California
RELATED LEGISLATION
Pending Legislation: SB 278 (Cabaldon, 2025) authorizes the sharing of HIV test information for the purpose of administering quality improvement programs designed to improve HIV care for Medi-Cal beneficiaries, including value-based payment programs and healthy behavior incentive programs, as provided. SB 278 is currently in the Senate Appropriations Committee.
SB 504 (Laird, 2025) authorizes a health care provider of a patient with an HIV infection that has already been reported to a local health officer to communicate with CDPH or a LHO in order to obtain public health recommendations on care and treatment or to refer the patient to services provided by CDPH. SB 504 is currently in the Senate Appropriations Committee.
Prior Legislation:
SB 1333 (Eggman, Ch. 472, Stats. 2024) revised and recast existing law to permit CDPH and LHDs to disclose personally identifying information in public health records for the coordination of, linkage to, or reengagement in care, as determined by CDPH or a LHD.
AB 2132 (Low, Ch. 951, Stats. 2024) See Comment 2.
AB 789 (Low, Ch. 470, Stats. 2021) See Comment 2.
PRIOR VOTES:
Senate Health Committee (Ayes 10, Noes 0)
**************
Testing Algorithm for Coccidioidomycosis (May 10, 2024) CDC, https://www.cdc.gov/valley-fever/hcp/testing-algorithm/index.html#:~:text=Recommended%20test%20methods,characteristics%20of%20test%20at%20facility. All internet citations are current as of April 14, 2025. ↑
Reported Cases of Valley Fever (April 24, 2024) CDC, https://www.cdc.gov/valley-fever/php/statistics/index.html. ↑
SENATE COMMITTEE ON HEALTH
Senator Caroline Menjivar, Chair
BILL NO: SB 297
AUTHOR: | Hurtado | ||
VERSION: | April 2, 2025 | ||
HEARING DATE: | April 9, 2025 | ||
CONSULTANT: | Melanie Moreno | ||
SUBJECT: Valley Fever Screening and Prevention Act of 2025
SUMMARY:
Requires the California Department of Public Health to annually analyze and identify regions with high rates of Valley Fever and to publish a list of high-incidence regions. Requires local health departments (LHDs) in high-incidence regions to ensure compliance with screening protocols for Valley Fever. Requires LHDs to conduct outreach to health care providers and the general public to raise awareness of Valley Fever risks, symptoms, and prevention strategies. Requires an adult patient receiving primary care services in a high incidence region to be offered a Valley Fever screening test. Requires health plans, insurers, and Medi-Cal to cover Valley Fever screening tests in high-incidence regions.
Existing law:
- Establishes the California Department of Public Health (CDPH), directed by a state Public Health Officer (PHO), to be vested with all the duties, powers, purposes, functions, responsibilities, and jurisdictions as they relate to public health and licensing of health facilities, as specified. Gives the PHO broad authority to detect, monitor, and prevent the spread of communicable disease in the state. [HSC §131050 and §120130]
- Requires each county board of supervisors to appoint a local health officer (LHO). Requires LHOs to enforce and observe orders and ordinances of the board of supervisors, pertaining to the public health and sanitary matters, orders, including quarantine and other regulations prescribed by CDPH, and statutes relating to public health. [HSC §101000 and §101030]
- Requires CDPH to establish a list of diseases and conditions to be reported to CDPH by LHOs, clinical laboratories, and health care providers (Valley Fever is on this list). Requires CDPH to specify the timeliness requirements related to the reporting of each disease and condition, and the mechanisms required for, and the content to be included in, these reports. [HSC §120130 and 17 CCR §2500, et seq.]
- Places reporting requirements on CDPH related to Valley Fever surveillance, including: attributing late-reported data to the year of diagnosis in future data reporting; collecting cases by April 15 of each year; reporting to LHOs about any removal of discrepant data; and, including an explanation for likely data changes between initial and final publication of data and an explanation for discrepancies. [HSC §120161, §120162 and §120163]
- Establishes the Department of Managed Health Care to regulate health plans under the Knox-Keene Health Care Service Plan Act of 1975 and the California Department of Insurance to regulate health insurers. Establishes the Medi-Cal program, which is administered by the Department of Health Care Services, and under which qualified low-income individuals receive health care services. [HSC §1340, et seq., INS §106, et seq. and WIC §14000, et seq.]
This bill:
- Requires CDPH to annually analyze and identify regions with high rates of Valley Fever using public health surveillance data. Requires CDPH to publish its first list of high-incidence regions for Valley Fever by March 1, 2027.
- Requires CDPH to provide LHDs in high-incidence regions with detailed infection data and standardized screening protocols for Valley Fever.
- Requires CDPH to develop and distribute evidence-based training materials on Valley Fever detection, diagnosis, and treatment for health care providers.
- Requires LHDs in identified high-incidence regions to ensure compliance with screening protocols for Valley Fever.
- Requires LHDs to conduct outreach to health care providers and the general public to raise awareness of Valley Fever risks, symptoms, and prevention strategies.
- Requires LHDs to annually report to CDPH, including the confirmed cases of Valley Fever, and relevant demographic and geographic data to support statewide tracking and response efforts.
- Requires, beginning January 1, 2028, an adult patient who receives primary care services in a facility, clinic, unlicensed clinic, center, office, or other setting where primary care services are provided, and in an identified high-incidence region for Valley Fever, to be offered a Valley Fever screening test, to the extent these services are covered under the patient’s health insurance, based on the latest screening indications recommended by the latest national clinical practice guidelines, unless the health care provider reasonably believes that one of the following conditions applies:
- The patient is being treated for a life-threatening emergency;
- The patient has previously been offered or has been the subject of a Valley Fever screening test, unless the health care provider determines that the screening test should be offered again;
- The patient lacks capacity to consent to a Valley Fever screening test; or
- The patient is being treated in an emergency department.
- Requires the offering of a Valley Fever screening test to be culturally and linguistically appropriate.
- Requires a health care provider, if a patient accepts the offer of a Valley Fever screening test and the test result is positive, to offer the patient follow-up health care or refer the patient to a health care provider who can provide follow-up health care. Requires follow-up health care to include diagnostic testing and care based on the latest national clinical practice guidelines recommended for Valley Fever management.
- Prohibits this bill from affecting the scope of practice of any health care provider or diminish any authority or legal or professional obligation of any health care provider to offer a Valley Fever screening test, or to provide services or care for the patient of a Valley Fever screening test. Prohibits a health care provider that fails to comply with these requirements of this bill from being subject to any disciplinary actions related to their licensure or certification, or to any civil or criminal liability, because of the health care provider’s failure to comply.
- Requires health plans, insurers, and Medi-Cal, after June 1, 2027, to cover Valley Fever screening tests in high-incidence regions. Prohibits deductibles, coinsurance, copayments, or any other cost-sharing requirement on this coverage. Requires the Medi-Cal mandate to be implemented only to the extent that any necessary federal approvals are obtained and federal financial participation is available and not otherwise jeopardized.
- Requires CDPH, by January 1, 2030 and every two years thereafter, to evaluate the effectiveness of the Valley Fever screening and prevention program and report its findings to the Legislature.
FISCAL EFFECT:
This bill has not been analyzed by a fiscal committee.
COMMENTS:
- Author’s statement. According to the author, Valley Fever is a growing public health crisis, yet too many cases go undiagnosed for too long. This bill ensures that Californians in high-incidence regions receive the early detection and care they deserve. By 2027, CDPH will identify the hardest-hit areas, giving communities the data they need to act. County health departments will standardize screening protocols and work with local health officers to educate providers and the public. For too many, a simple test could mean the difference between a quick recovery and years of misdiagnosis. That’s why, starting in 2028, primary care providers in high-risk regions must offer Valley Fever screenings to adults. No one should have to choose between affordability and their health—so beginning in 2027, insurance plans, including Medi-Cal (pending federal approval), will cover these tests without cost-sharing. Public health should be proactive, not reactive. This bill strengthens California’s response by requiring ongoing program assessments and legislative reports to ensure effectiveness. By equipping communities with better data, removing cost barriers, and prioritizing early detection, this bill takes a critical step toward reducing the devastating impact of Valley Fever. Californians deserve a healthcare system that catches Valley Fever early—before it catches them.
- Background. According to the Centers for Disease Control and Prevention (CDC), Valley Fever is an infection caused by the fungus coccidioides. The fungus lives in the soil in the southwestern U.S., south-central Washington state, and parts of Mexico and Central and South America. People can get Valley Fever by breathing in microscopic coccidioides spores from the air, although some people never get sick from it. It does not spread from person-to-person or between people and animals. Valley Fever is detected through blood or skin tests and causes typical lung infection symptoms, like cough and fever. Certain groups of people may be at higher risk for developing the severe forms of Valley Fever, such as: people with weakened immune systems, pregnant women, people who have diabetes, those over 60, and Black or Filipino people. The CDC states that many people get better without medication within a few months, but antifungal medications is prescribed for people with more serious infections or those with risk factors for severe infection. Because Valley Fever has the same symptoms as pneumonias, it is often misdiagnosed or undiagnosed, which can lead to ineffective treatments or delays in treatment.
In 2022, there were 17,612 reported cases of Valley Fever in the U.S., with 7,459 of those in California. According to the CDC, rates are highest among people 60 years and older. On average, there were approximately 200 Valley Fever-associated deaths each year from 1999 to 2021. The number of Valley Fever cases reported likely underestimates the true number of cases, and tens of thousands more illnesses likely occur because many patients are not tested for Valley fever. In highly endemic areas such as the Phoenix and Tucson metropolitan areas, Valley Fever causes an estimated 15% to 30% of community-acquired pneumonias.
- UC Berkeley study. A UC Berkeley study published in March 2025 in the Journal of the Royal Society Interface found that longer, drier summers in California can extend the transmission season of Valley Fever. The study finds that shifts in seasonal rainfall patterns (like those anticipated with climate change) shift the start of the transmission season earlier and prolong its duration. Researchers analyzed historical Valley Fever case data alongside climate records to examine how temperature and precipitation patterns impact the timing and duration of transmission seasons. Their findings suggest that drier springs accelerate the onset of transmission seasons and drier falls delay the end of the transmission season. The study’s principal investigator stated that “healthcare providers should be especially vigilant during and following prolonged dry seasons, as these periods may correspond with heightened disease transmission.”
- CDC testing recommendations. According to the CDC, Valley Fever cannot be reliably distinguished from other causes of respiratory illness by signs or symptoms alone. The CDC recommends the consideration of testing on an initial presentation of community-acquired pneumonia or erythema nodosum (an inflammatory disorder characterized by tender bumps under the skin) following recent respiratory symptoms who: have a link to known outbreak; or, who live in or recently traveled to the highly endemic regions (like desert regions of South-Central Arizona and the San Joaquin Valley of California). The CDC also recommends testing in patients with community-acquired pneumonia who live in or recently traveled to an endemic area and have symptoms that did not improve following antibiotics.
- Prior legislation. SB 1231 (Caballero of 2022) would have required CDPH to create a California Standard Diagnostic for Valley Fever and to conduct an awareness campaign to communicate with LHDs, providers, and the public about the Diagnostic for Valley Fever. SB 1231 was held on the Assembly Appropriations Committee suspense file.
AB 1787 (Salas and Fong, Chapter 229, Statutes of 2018) places reporting requirements on CDPH related to Valley Fever surveillance, including: attributing late-reported data to the year of diagnosis in future data reporting; collecting cases by April 15 of each year; reporting to LHOs about any removal of discrepant data; and including an explanation for likely data changes between initial and final publication of data, and an explanation for discrepancies between data reported by an LHO and data reported by CDPH.
AB 1788 (Salas and Grayson, Chapter 230, Statutes of 2018) permits CDPH, for the purpose of Valley Fever case reports, to use a laboratory criteria for diagnosis, with or without clinical criteria.
AB 1789 (Salas and Fong of 2018) would have required the Occupational Safety and Health Standards Board to adopt Valley Fever standards for state public works projects, as specified. AB 1789 was held on the Assembly Committee of Appropriations suspense file.
AB 1790 (Salas and Grayson, Chapter 338, Statutes of 2018) enacted the Valley Fever Education, Early Diagnosis, and Treatment Act, and required CDPH to conduct an awareness campaign to LHDs, providers, and the public. AB 1790 became inoperative on January 1, 2021.
AB 1279 (Salas of 2017) would have required CDPH to develop and implement public outreach programs to educate the public about Valley Fever. AB 1279 was vetoed by Governor Brown, who stated: “The department already provides fact sheets, brochures, posters and other educational materials to raise awareness of this disease. Expanding this program would necessitate additional resources which should be considered along with other funding requests as part of the budget process.”
SB 115 (Fuller of 2015), SB 1044 (Fuller of 2014), SB 492 (Ashburn of 2005), SB 1027 (Ashburn of 2003), and AB 1955 (Ashburn of 2002) would have appropriated $1 million from the General Fund to CDPH for purposes of Valley Fever vaccine research. SB 115 was held on the Senate Committee of Appropriations suspense file. SB 1044 was referred to Banking and Finance but never acted upon. SB 492, SB 1027, and AB 1955 were held on the Assembly Committee of Appropriations suspense file.
- Support. Supporters write that farmworkers, construction crews, and other outdoor laborers are especially vulnerable to Valley Fever, as they may be unknowingly inhaling spores. Without proper testing and diagnosis, these individuals can suffer debilitating illness, miss work, and face mounting medical costs. Climate change is also contributing to Valley Fever’s rapid spread. Rising temperatures and prolonged droughts create conditions that allow coccidiodes fungus to thrive. As a result, communities and towns that have never before faced the threat of Valley Fever are becoming hotspots for the disease. Valley Fever is an urgent environmental justice issue for the communities in the southern San Joaquin Valley, which has historically experienced some of the highest infection rates in the country. There is evidence that communities of color (particularly Black and Filipino communities) and vulnerable populations (such as pregnant and immunocompromised people) are at higher risk of infection than the general population. Despite its growing prevalence, awareness of Valley Fever remains low. Misdiagnosis is common, leading to delay in treatment and unnecessary suffering for patients. Public health agencies face significant challenges in tracking cases due to inconsistent testing and reporting practices. In the San Joaquin Valley, thousands of cases go unreported each year, leaving public health officials with an incomplete picture of the disease’s true impact. The threat of Valley Fever will continue to grow and affect more communities as climate change creates more conditions for infection to spread. Proactive measures like this bill aim to tackle this issue by requiring the CDPH to identify and share data on regions with high Valley Fever rates, mandating screenings in high-incidence areas when medically necessary, and ensuring health insurance providers, including Medi-Cal, cover screenings at no additional cost to patients.
- Opposition. The California Medical Association (CMA) writes that they oppose a mandate requiring physicians to offer Valley Fever testing to all primary care patients in high-incidence regions. The CMA states that this mandate overrides a physician’s clinical judgment in determining whether testing is appropriate for a given patient. For context, Valley Fever is typically a mild infection for most individuals, with 90% to 95% of those infected experiencing mild symptoms that resolve without testing or treatment. Only an estimated 5% to 10% of infected individuals experience worsening or severe symptoms requiring medical intervention, with those who have weakened immune systems or underlying health conditions being at the highest risk for developing severe symptoms. Additionally, mandating physicians to offer this testing would result in unnecessary screenings for asymptomatic individuals or those with mild symptoms, even when offering the test goes against clinical judgment. This could contribute to longer wait times for all patients awaiting laboratory results – a serious concern, particularly for those with severe Valley Fever symptoms or for those experiencing other health issues where timely testing is essential to their recovery. Unlike other conditions such as Tuberculosis, Valley Fever currently lacks a risk assessment tool, making clinical discretion even more crucial. The CMA states that it’s critical that we not remove a physician’s clinical judgement to offer Valley Fever testing to patients in high-incidence regions, as appropriate.
- Oppose unless amended. The County Health Executives Association of California (CHEAC) writes that this bill requires LHDs to ensure compliance with Valley Fever screening protocols, but their members do not play an enforcement role with local health care providers; rather, LHDs collect data and serve as an advisory resource for the local medical community on communicable diseases. Ensuring that health care providers comply with screening protocols falls under the jurisdiction of the Medical Board of California, which is responsible for overseeing health care provider compliance with the law. They request an amendment to delete this provision.
- Amendments. The author requests the Committee approve amendments to address concerns raised by CHEAC as follows:
HSC 122481 (a): “Local health departments in high-incidence regions, as identified pursuant to Section 122480, shall ensure compliance with screening protocols for valley fever.”
(b) Local health departments in high incidence areas shall conduct outreach to health care providers and the general public to raise awareness of valley fever risks, symptoms, and prevention strategies.
(c) Local health departments shall annually report to the State Department of Public Health confirmed cases of valley fever. and relevant demographic and geographic data to support statewide tracking and response efforts.
To align this bill with other law that prohibits cost sharing, the author should amend as follows:
HSC 1367.57.
(a) A health care service plan contract, except for a specialized health care service plan contract, that is issued, amended, delivered, or renewed on or after June 1, 2027, shall cover a valley fever screening test, provided pursuant to 1316.8, tests in high-incidence regions for valley fever, as identified by the State Department of Public Health pursuant to Section 122480.
(b) (1) A health care service plan contract shall not impose a deductible, coinsurance, copayment, or any other cost-sharing requirement on the coverage provided pursuant to this section.
(2) Notwithstanding paragraph (1), if a health care service plan contract is a high deductible health plan, as defined in Section 223(c)(2) of Title 26 of the United States Code, the contract shall not impose a deductible, coinsurance, or any other cost sharing on a valley fever screening test, unless not applying the deductible, coinsurance, or other cost sharing would conflict with federal requirements for high deductible health plans.
INS 10123.25.
(a) A health insurance policy, except for a specialized health insurance policy, that is issued, amended, delivered, or renewed on or after June 1, 2027, shall cover a valley fever screening test, provided pursuant to 1316.8, tests in high-incidence regions for valley fever, as identified by the State Department of Public Health pursuant to Section 122480 of the Health and Safety Code.
(b) A (1) health insurance policy shall not impose a deductible, coinsurance, copayment, or any other cost-sharing requirement on the coverage provided pursuant to this section.
(2) Notwithstanding paragraph (1), if a health care service plan contract is a high deductible health plan, as defined in Section 223(c)(2) of Title 26 of the United States Code, the contract shall not impose a deductible, coinsurance, or any other cost sharing on a valley fever screening test, unless not applying the deductible, coinsurance, or other cost sharing would conflict with federal requirements for high deductible health plans.
SUPPORT AND OPPOSITION:
Support: Altura Centers for Health
California Health Collaborative
Center on Race, Poverty, & the Environment
City of Avenal
MyCare Foundation
Saint Agnes Medical Center
Valley Fever Americas Foundation
Valley Fever Institute at Kern Medicine
Oppose: County Health Executives Association of California (unless amended)
California Medical Association
-- END --
Bill Author
Bill Co-Author(s):